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ABSTRACT 
Melanocortin receptors (MCRs) are members of G - protein coupled receptor (GPCR) family. In 
vertebrates large proportion of GPCRs encoding genes are intronless or have a lower density of introns when 
compared with GPCRs of invertebrates. MCRs play an important role in a variety of essential functions such 
as the regulation of pigmentation, energy homeostasis, and steroid production. Among other MCRs 
adrenocorticotropic hormone (ACTH) receptor (MC2R) stands out with its highly specific membrane 
expression that is limited to adrenal cells and unlike the other members of MCR family, that recognize 
different melanocortin peptides, the ACTHR solely binds to ACTH. The aim of this research was to study the 
evolution of MCR family in context with evolutionary expansion of whole GPCR group and identify 
structural regions of ACTHR that determine its functional dissimilarities compared with, other MCRs. 
During the search of to ancestral similar MCRs in bony fishes: Takifugu rubripes and Danio rerio orthologs 
of all five MCR subtypes were identified, however there were no MCR identified in tunicates: Coina 
intestinalis and Coina savignyi nor in nematode: Caenorhabditis elegans. These findings combined with 
information of recently discovered MCRs in lamprey: Lampetra fluviatilis allow to conclude that MCRs 
appeared on an early stage of vertebrate evolution and this family evolved particularly rapidly soon after the 
split of lamprey and mammalian lineage. It is also concluded that specialisation of ACTHR took place during 
the same period of rapid evolution and to identify regions of this protein that determine its specificity in total 
15 chimeric receptors were created by replacement of selected ACTHR domains with corresponding parts of 
MC4R. Chimeric receptors were tested for their membrane localization and ability to bind NDP-MSH and 
ACTH (1-24) and induce cAMP response. The results indicate that N-terminal part of ACTHR significantly 
decreases the membrane trafficking and third and fourth transmembrane region is main determinant of 
ACTHR intracellular trapping. In addition it was found that the fourth and fifth transmembrane domains in 
the ACTHR are involved in ACTH binding selectivity. During the research an analysis method to quantify 
cell membrane localization of recombinant receptors fused with enhanced green fluorescent protein from the 
results of confocal fluorescent microscopy was developed 
KOPSAVILKUMS 
Melanokortīna receptori (MCR) pieder pie ar G-proteīnu saistīto receptoru (GPCR) saimes. 
Mugurkaulniekos liela daļa šīs saimes receptorus kodējošo gēnu nesatur intronus vai arī tiem, salīdzinot ar 
bezmugurkaulniekiem, ir zemāks intronu blīvums. MCR ir svarīga loma tādu nozīmīgu funkciju kā, 
pigmentācija, enerģijas homeostāze asteroīdu produkcija regulācijā. Starp citiem MCR adrenokortikotropā 
hormona receptors (ACTHR) izceļas ar savu specifisko membrānas ekspresiju, kas tiek veikta tikai virsnieru 
šūnās, un atšķirībā no citiem MCR, kas atpazīst dažādus melanokortīna peptīdus, ACTHR saistās tikai ar 
adrenokortikotropo hormonu (ACTH). Šī darba mērķis bija pētīt MCR saimes evolūciju visas GPCR grupas 
evolucionārās ekspansijas kontekstā un identificēt strukturālos ACTHR reģionus, kas nosaka tā funkcionālās 
atšķirības. Darba gaitā ,meklējot priekšteču MCR līdzīgus receptorus kaulzivīs Takifugu rubripes un Danio 
rerio, tika atrasti ortologi visiem pieciem zīdītāju MCR, taču MCR netika atrasti nedz tunikātos Ciona 
intestinalis un Ciona savignyi, nedz nematodē Caenorhabditis eleagns. Apvienojot šos atklājumus ar nesen 
publicēto informāciju par MCR nēģī Lampetra fluviatilis bija iespējams secināt, ka MCR radās agri 
mugurkaulnieku attīstības sākumposmā un šī saime attīstījās īpaši strauji drīz pēc nēģu un zīdītāju priekšteču 
šķelšanās. Vēl tika secināts, ka ACTHR specializācija arī noritēja šajā pašā mugurkaulnieku evolūcijas 
posmā un, lai identificētu receptora specifiskumu nosakošos reģionus kopumā tika izveidoti 15 himeri 
receptori, kuros izvēlēti ACTHR reģioni tika aizvietoti ar homologiem MC4R reģioniem. Visiem himerajiem 
receptoriem tika veikti membrānas lokalizācijas, NDP-MSH un ACTH (1-24) saistīšanās un funkcionālās 
aktivitātes testi. Iegūtie rezultāti norādīja, ka ACTHR N-terminālā daļa ievērojami samazināja receptora 
transportu uz šūnas membrānu, un, ka trešā un ceturtā transmembrānas domēnu reģions nodrošina ACTHR 
iekššūnas aizturi. Papildus tika noteikts, ka ACTHR ceturtā un piektā transmembrānas domēnu reģions ir 
iesaistīs ACTH saistīšanas selektivitātes nodrošināšanā. Pētījumu gaitā arī tika izstrādāta analītiska metode ar 
uzlaboti zaļi fluorescējošo proteīnu sajūgtu rekombinantu receptoru lokalizācijas kvantifikācujai izmantojot 
konfokālo fluorescences mikroskopiju. 
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USED ABBREVATIONS 
7TM  .............7 transmembrane domain region 
aa ..................amino-acid 
ACTH ...........Adrenocorticotropic hormone 
ACTHR ........Adrenocorticotropic hormone receptor 
AF-WGA ......Alexa Fluor™ 633 labeled wheat germ agglutinin 
AgRP ............Agouti related protein 
ARG .............ancestral receptor group  
ASIP .............Agouti or Agouti siganlling prrotein 
C-terminus ....carboxyl-terminus 
CNS ..............central nervous system 
cAMP ...........cyclic adenosine monophosphate 
DNA .............deoxyribonucleic acid 
EC50 .............effective concentration (at which is produced 50% of of maximum response) 
Ki ..................inhibition constant 
Kd .................dissociation constant 
Bmax ............Amount of ligand required to saturate a population of receptor 
EGFP ............enhanced green fluorescent protein 
GFP...............green fluorescent protein 
ER .................endoplasmatic reticulum 
FCS ...............foetal calf serum 
Gα ............... alpha subunit of heterotrimeric G-protein 
Gβ ............... beta subunit of heterotrimeric G-protein 
Gγ ............... gamma subunit of heterotrimeric G-protein 
GDP ............ guanidine diphosphate 
GPCR ...........G-protein coupled receptor 
GTP ............ guanidine triphosphate 
HMM ............The Hidden Markov Model  
kb ..................Kilo-bases  
MC ................melanocortin 
MCR .............melanocortin receptor 
MC#R ......... melanocortin receptor type # 
MC2R ...........see ACTHR  
MP ................Maximum Parsimony  
MRAP...........melanocortin receptor accessory protein 
MRAP-α .......melanocortin receptor accessory protein alpha isoform 
MRAP-β .......melanocortin receptor accessory protein beta isoform 
MRAP2.........melanocortin receptor accessory protein type 2 
MSH .............Melanocyte-Stimulating Hormone 
mRNA ........ messenger ribonucleic acid 
N-terminus ....amino-terminus 
NDP-MSH ....[Nle4 D-Phe7] alpha-MSH 
POMC...........proopiomelanocortin precursor 
RNA ........... ribonucleic acid 
ROI ...............regions of interest 
RT-PCR ........reverse transcription polymerase chain reaction 
SDS...............sodium dodecyl sulfate 
TM ................transmembrane domain 
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INTRODUCTION 
GPCRs are one of the largest protein families in the mammalian genome with over 
800 genes in humans. GPCRs detect extracellular signals and transduce them into the cell 
through the activation of heterotrimeric G-proteins. This family includes receptors for 
many hormones, neurotransmitters, chemokines, calcium ions, and sensory molecules. All, 
currently known, GPCRs are sharing the same overall seven α-helical transmembrane 
(TM) domain core structure. The Rhodopsin family is the largest sub-family among 
GPCRs. There are no Rhodopsin GPCRs in plants and this group can only be found in 
animals. Rhodopsin GPCR family is one of the gene families in mammals with a large 
proportion of intronless genes. This is very uncommon, since the overall density of 
intronless genes in human is only 12.3%. Usually the intronless state is an indicator that a 
particular gene family is undergoing active changes and this peculiarity can be used to 
study the evolutionary history of introns. The number of GPCR genes has increased 
approximately six fold from nematodes to mammals.  
The melanocortin system is involved in regulation of many different physiological 
functions, including the formation of pigmentation, adrenocortical steroidogenesis, energy 
homeostasis, exocrine secretion, sexual functions, inflammation and immunomodulation, 
thermoregulation and cardiovascular regulation. Term “melanocortin” is referred to 
peptides originated from proopiomelanocortin precursor (POMC), which exhibits 
melanotropic and adrenocorticotropic activity. MCs are produced mainly in frontal and 
intermediate lobe of pituitary. There are five types of melanocortin receptors (MCRs) that 
are all members of Rhodopsin GPCRs family and on the level of amino-acid sequence all 
MCRs share 39-61% identity. Despite this similarity all MCRs are displaying unique 
expression pattern and pharmacological profile, binding various melanocortins with 
distinctive affinities. ACTHR is the most specialized MCR, it is specifically binding only 
ACTHR and is predominantly expressed in adrenal cortex, where it mediates the effect of 
ACTH on glucocorticoid synthesis. Genetic defects in ACTHR gene are causing Familial 
glucocorticoid deficiency (FGD) - a rare autosomal recessive disorder. 
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The aim of this research was to study the evolution of MCR family and identify 
structural regions of ACTHR that determine its functional dissimilarities compared with, 
other MCRs. To reach this goal following tasks were established: 
1. Identify MCRs in bony fishes Takifugu rubripes and Danio rerio; 
2. Determine functional properties of Takifugu rubripes MCR which is most similar to 
mammalian ACTHR; 
3. Search for “ancestral receptors groups” that would be present in vertebrates, 
tunicates and nematodes and identify the group which could be ancestral to MCRs; 
4. Search for the explanations concerning existence of introns in Takifugu rubripes 
MCR genes and general intron absence in vertebrate GPCR genes; 
5. Create chimeric receptors by replacement of selected ACTHR domains with 
corresponding parts of MC4R, determine their pharmacological properties upon 
binding and activation with NDP-MSH and ACTH and quantify their membrane 
trafficking; 
6. Identify functional domains of ACTHR that determine its expression and ligand 
binding selectivity. 
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1 SUMMARY OF THE EXISTING SCIENTIFIC INFORMATION IN 
THE RESEARCH AREA 
1.1 G-protein coupled receptors (GPCR) 
GPCRs are one of the largest protein families in the mammalian genome with over 
800 genes in humans (Fredriksson et al. 2003). GPCRs detect extracellular signals and 
transduce them into the cell using activation of GDP–GTP (guanidine diphosphate-
guanidine triphosphate) exchange on heterotrimeric G-proteins. This family includes 
receptors for many hormones, neurotransmitters, chemokines, calcium ions, and sensory 
molecules. The Rhodopsin family is the largest sub family among GPCRs There are no 
Rhodopsin GPCR in plants (Fredriksson et al. 2005) and this group of GPCRs can be 
found only in animals. The number of GPCR gene has increased approximately six fold 
from nematodes to mammals (Fredriksson et al. 2005). 
1.1.1 Structure 
Despite the wide chemical and functional variety of the bound signal molecules, all, 
currently known, GPCRs are sharing the same overall seven α-helical transmembrane 
(TM) domain core structure (Fig.1). (Pierce et al. 2002) Such similarity in structure 
indicates that all GPCRs are most certainly evolutionary related and moreover it has been 
discovered that bacteriorhodopsin also has a 7TM, but instead of coupling to a G-protein, it 
functions as a light driven proton pump. However such structural similarity suggests that it 
might be related to ancestral GPCR. 
N
VIIVIVIVIIIIII
C
Extracellular side
Cytoplasmatic side  
Figure 1. Schematical depiction of G-protein coupled receptor structure: seven cell 
membrane spanning α-helical transmembrane domains, N-termini is always located in 
extracellular side and C-terminus is always located in cytoplasmatic side. 
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First insight into the structural composition of GPCRs came in early 1980’s. The 
breakthrough, discovery of complete amino-acid sequence of bovine rhodopsin, was 
achieved by two independent groups simultaneously (Ovchinnikov et al. 1982; Hargrave et 
al. 1983) and it was followed by molecular cloning of all four human opsins (Nathans et al. 
1984; Nathans et al. 1986) and the hamster β-adrenergic receptor (Dixon et al. 1986). At 
this point it was noticed that secondary structure predictions of all these proteins shared 
similar structural pattern that was formed by seven hydrophobic membrane spanning α-
helices, extracellular N-termini and intracellular C-termini. Discoveries of other around 70 
similar receptors, which took place during the next decade, confirmed that such secondary 
structure is common to all members of GPCR super-family. (Probst et al. 1992). 
Nevertheless, despite identification of such, for that time, large number of new GPCRs, it 
took ten years of studies before the first insight into the three-dimensional tertiary structure 
was gained. It was accomplished at first by acquiring of 9Å projection map of bovine 
rhodopsin, which through electron crystallography of two-dimensional crystals (Schertler 
et al. 1993) and then by combining these findings with the sequence analysis, in order to 
allocate the individual TMs (Baldwin 1993). The rhodopsine was yet again used as model 
GPCR not for the historical reasons but because of its rigid structure caused by covalently 
bound ligand. In these studies it was acknowledged that TM domains of GPCRs are indeed 
organised in bundle forming a cavity in the centre, which could possibly act as ligand 
binding pocket for most of the GPCRs. For the next almost ten years this model along with 
the few later low resolution models served as the only sources of GPCR structure 
information and were extensively used in comparison modelling of other –similar 
receptors. (Costanzi et al. 2009) The next big breakthrough was achieved in 2000 when 
Palczewski and his colleagues acquired the first high resolution (2,8Å) X-ray crystal 
structure of bovine rhodopsin. Analysis of this model revealed exact geometry of each TM, 
geometries of large portion of intracellular and extracellular domains (loops, N- and C- 
termini), number of intramolecular interactions including disulfide bridge that connects 
extracellular side of TM3 with the second extracellular loop, as well as structures, in 
following years identified as rhodopsin specific (β-hairpin conformation for the second 
extracellular loop). (Palczewski et al. 2000) (Fig. 2) 
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Figure 2. Ribbon drawings of rhodopsin. (A) Parallel to the plane of the membrane 
(stereo view). A view into the membrane plane is seen from the cytoplasmic (B) and 
intradiscal side (C) of the membrane. (Figure and figure legend are from: Palczewski et 
al. 2000) 
After publication of the x-ray structure of rhodopsin, just like in a case with the low 
resolution model, was extensively used as template for the homology modelling of other 
GPCRs. Such models were mainly supported with the indirect experimental data acquired 
by usage of mutation techniques. However, two problems were undermining the credibility 
these results when used for modelling of GPCR-ligand complexes. First, these models 
could not be validated due to the lack of second-reference GPCR, and, second, since the 
structure acquired by Palczewski and his colleagues was the one of inactive rhodopsin, 
there were no information regarding the changes receptor is undergoing during activation 
process. (Costanzi et al. 2009) 
In the following years the changes in structure of receptor during activation process 
have been studied very intensively using electron crystallography (Krebs et al. 2003; 
Ruprecht et al. 2004) and solid-state nuclear magnetic resonance (NMR) spectroscopy 
(Crocker et al. 2006). Results gained from these experiments suggested that the signal 
transduction promoting large scare conformational changes during activation of the 
receptor are occurring suddenly rather than gradually and that changes in conformation 
during the first phases of the activation process are concerning only several amino –acid 
residues located within the receptor binding pocket.  
The most recent and ground breaking advances in GPCR structure discovery were 
achieved in the last few years. There are 10 new high-resolution structures solved: one of 
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thermo-stabilised bovine rhodopsin (Standfuss et al. 2007), two of bovine rhodopsin in an 
active-like state (Park et al. 2008; Scheerer et al. 2008), three of the human β2 adrenergic 
receptor (Cherezov et al. 2007; Rasmussen et al. 2007; Hanson et al. 2008), one of the 
human adenosine A2a receptor (Jaakola et al. 2008), one of the turkey β1 adrenergic 
receptor (Warne et al. 2008) and two of the squid rhodopsin which unlike previous ones is 
a Gq coupled receptor (Murakami et al. 2008; Shimamura et al. 2008). 
Such high rate of success, if compared to previous period of researches, can be 
mainly attributed by the usage of novel GPCR stabilisation and acquisition approaches. 
The stabilisation techniques (including thermal-stabilisation) comprised addition of 
receptor conformation stabilising ligands, lipids or antibodies at the stage of crystallisation, 
as well as modification of desirable GPCRs - proteolysis, mutatagenesis, deletion of 
flexible regions or insertion of highly structured ones was usually employed. Receptors 
modified in this way were over-expressed and purified from recombinant mammalian or 
insect cell expression systems. (Tate et al. 2009) 
It was self-evident that such large amount of new discoveries led to comparison of 
different GPCR structures. During these studies it was acknowledged that overall helical 
framework and positions of helical irregularities of the analysed receptors indeed are well 
conserved, supporting the previously created models that were based on the first rhodopsin 
x-ray structure. However the extracellular surfaces of rhodopsin and hormone receptors 
were significantly different. Binding pocket of rhodopsin is closed/covered with the 
structure formed by N-terminus of the receptor, β-hairpin structure in the second 
extracellular loop and various elements of other extracellular loops, while binding pockets 
of hormone receptors are open to permit access of ligand. (Tate et al. 2009) 
Regarding the activation of the GPCRs, it was established that in the inactive state 
two of Rhodopsin GPCRs (Class A GPCRs) characteristic motifs (E/D)RY, located in 
intracellular part of TM3, and NPxxY, located in intracellular part of TM7, are spatially 
separated by a “wall” of hydrophobic amino-acid residues located in intracellular part of 
TM2 and TM6. After the binding of ligand a series of intrahelical rearrangements are 
taking place. During these rearrangements “the wall” between (E/D)RY and NPxxY motifs 
is removed thus permitting the formation of structure crucial for G-protein binding. (Fig. 3) 
(Tate et al. 2009) 
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Figure 3. Four interhelical interaction networks important for receptor activation of 
Class A GPCRs, depicted in the structure of β1AR. Top panel: the rotamer toggle 
switch in TM6, formed by W6.48 and F6.52. Its rearrangement upon agonist binding 
has been related to the movement of TM6 (Rao et al. 1996). Left panel: a complex 
hydrogen bond network between TM1, TM2, TM6 and TM7 involving some of the 
most highly conserved residues in Class A GPCRs (N1.50, D2.50, W6.48, (N/S)7.45, 
N7.49, P7.50) and water molecules. The position of the water molecules has been 
derived from the structure of the β2AR. Right panel: a TM3/TM5 interaction between 
S5.46 and T3.37 can be directly disrupted by agonist binding, which could lead to the 
rearrangement of the Pro-induced unwinding of TM5 (stabilised by I3.40), and to a 
conformational change in the cytoplasmic side of TM5. A similar network is present in 
rhodopsin (Shi et al. 2002). These networks define three possible independent pathways 
of activation (A, B and C) that converge on the (E/D)RY motif. Bottom panel: detail of 
the (E/D)RY region in the inactive (β1AR structure, left) and active (Gαt peptide-bound 
opsin structure, right) conformations. In the inactive state (left), R3.50 is constrained in 
an energetically unfavourable conformation because of the ionic interaction with 
E/D3.49. The (E/D)RY motif in TM3 is isolated from the NPxxY motif in TM7 by a 
wall of bulky hydrophobic residues of TM2 and TM6 (spheres). Upon activation (right), 
TM6 moves away from the bundle and the NPxxY motif in TM7 rearranges, bringing 
Y7.53 close to R3.50. This rearrangement is probably related to the rearrangement of 
the water cluster (left panel), as water molecules seem responsible for stabilising the π-
helix segment observed in the inactive state (Pardo et al. 2007). (Figure and figure 
legend are from: Tate et al. 2009) 
1.1.2 Heterotrimeric G-protein 
At the present moment there have been identified 21 α, 6 β and 12 γ (Tab. 1) 
mammalian heterotrimeric G-protein subunits. Most of those are encoded by separate 
genes while some are formed through alternative splicing. (Downes et al. 1999; Milligan et 
al. 2006) Since the Gα subunit is the one that most frequently determines the type of 
affected intracellular signalling pathway, it has been studied more intensively than other 
subunits. Basing on primary sequence similarity, all Gα were divided in four main classes: 
Gsα, Gi/oα, Gq/11α and G12/13α (Tab. 1). (Simon et al. 1991) However the structural studies 
revealed that despite the class membership all Gα has the same conserved protein fold, 
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formed by GTPase domain and helical domain. Structure of the GTPase domain, main 
function of which is hydrolysis of GTP, is highly similar to structure found in other G-
proteins including ones of the Ras superfamily. The helical domain on the other hand is 
unique to Gα. It is formed by bundle of six α-helices and covers nucleotide binding pocket 
as a lid, thus burying bound nucleotides in interior of the protein. The vast majority of Gα 
are post-translationally modified with the fatty acid at their N-termini, some are 
additionally myristoylated at their N-termini, and these modifications determine membrane 
localisation of particular Gα as well as some protein-protein interactions. (Oldham et al. 
2008)  
Gβ contains seven WD40 sequence repeats that form seven-bladed β-propeller 
structure, which is known to serve as a platform for the protein complex assembly or 
mediator of transient interplay among other proteins. N-terminus of Gβ is folded in α-helix 
that forms the coiled-coil with the N-terminus of Gγ. The C-terminus of Gγ is also bound 
to Gβ (to blades five and six) thus forming a complex that can only be separated in highly 
denaturing conditions. All Gγ are post-translationally modified by isoprenylation of their 
N-termini. (Oldham et al. 2008) It should also be mentioned that although most of the Gβ 
can form the complex with the most of Gγ, not all of ~60 possible combinations have been 
detected this far. (Clapham et al. 1997) 
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Table 1. The family of mammalian heterotrimeric G-protein subunits: function and regulation (Table and table legend are from Milligan et al. 2006) 
Family Subtype Effectors Expression Disease relevance Pharmacological 
modulation 
Gsα Gs(S)α 
Gs(L)α 
Gs(XL)α 
Golfα 
Adenylyl cyclases ↑ (Gs,s(XL),olfα) 
Maxi K channel ↑ (Gsα) 
Src tyrosine kinases (c-Src, Hck) ↑ (Gsα) 
GTPase of tubulin ↑ (Gsα) 
Gsα: ubiquitous 
Golfα: olfactory neurons, certain 
CNS ganglia; digestive and 
urogenital tract 
Gs(XL)α: brachydactyly, trauma-related bleeding tendency, neurological 
problems 
Gsα: McCune–Albright syndrome, cholera, pseudohypoparathyroidism 
type Ia/b, testotoxicosis, adenomas of pituitary and thyroid 
Gsα: CTX 
Golfα: CTX 
Gi/oα Go1α 
Go2α 
Gi1–i3α 
Gzα 
Gt1/2α 
Ggustα 
Adenylyl cyclase ↓ (Gi,o,zα) 
Rap1GAPII-dependent 
ERK/MAPkinase activation ↑ (Giα) 
Ca2+ channels ↓ (Gi,o,zα) 
K+ channels ↑ (Gi,o,zα) 
GTPase of tubulin ↑ (Giα) 
Src tyrosine kinases (c-Src, Hck) ↑ (Giα) 
Rap1GAP ↑ (Gza) 
GRIN1-mediated activation of Cdc42 ↑ (Gi,o,zα) 
cGMP-PDE ↑ (Gtα) 
Ggustα: ? 
Go1–2α: neurons, neuroendocrine 
cells, astroglia, heart 
Gi1–i3α: neurons and many others 
Gzα: platelets, neurons, adrenal 
chromaffin cells, neurosecretory 
cells 
Gt1α: rod outer segments, taste buds 
Gt2α: cone outer segments 
Ggustα: sweet and/or bitter taste buds, 
chemoreceptor cells in the 
airways 
Giα: whooping cough, adrenal and ovarian adenomas 
Gtα: congenital cone dysfunction, night blindness 
Go(1/2)α: PTX 
Gi1-i3α: PTX 
Gzα: ? 
Gt1/2α: PTX, CTX 
Ggustα: PTX 
Gq/11α Gqα 
G11α 
G14α 
G15α 
G16α 
Phospholipase Cb isoforms ↑ 
p63-RhoGEF ↑ (Gq/11α) 
Bruton’s tyrosine kinase ↑ (Gqα) 
K+ channels ↑ (Gqα) 
 
Gq/11α: ubiquitous 
G15/16α: hematopoietic cells 
Gq/11α: dermal hyperpigmentation and 
melanocytosis? 
 
Gq/11α: YM-254890 
G14α: ? 
G15α: ? 
G16α: ? 
G12/13α G12α 
G13α 
Phospholipase D ↑ 
Phospholipase Ce ↑ 
NHE-1 ↑ 
iNOS ↑ 
E-cadherin-mediated cell adhesion: ↑ 
p115RhoGEF ↑ 
PDZ-RhoGEF ↑ 
Leukaemia-associated RhoGEF (LARG) ↑ 
Radixin ↑ 
Protein phosphatase 5 (PP5) ↑ 
AKAP110-mediated activation of PKA ↑ 
HSP90 ↑ 
Ubiquitous Recent SNPs identified but no disease correlation yet 
 
G12α: ? 
G13α: ? 
Gβ/γ β1–5 
γ1–12 
PLCbs ↑ 
Adenylyl cyclase I ↓ 
Adenylyl cyclases II, IV, VII ↑ 
PI-3 kinases ↑ 
K+ channels (GIRK1,2,4) ↑ 
Ca2+ (N-, P/Q-, R-type) channels ↓ 
P-Rex1 (guanine nucleotide exchange factor for the small GTPase Rac) ↑ 
c-Jun N-terminal kinase (JNK) ↑ 
Src kinases ↑ 
Tubulin GTPase activity ↑ 
G-protein-coupled receptor kinase recruitment to membrane ↑ 
Protein kinase D ↑ 
Bruton’s tyrosine kinase ↑ 
p114-RhoGEF ↑ 
β1γ1: retinal rod cells 
β3γ8: retinal cone cells 
β5: neurons and neuroendocrine 
organs 
β5(L): retina 
Most cell types express multiple β 
and g subtypes 
Gβ3: atherosclerosis, hypertension, metabolic syndrome Gβγ: ? 
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1.1.3 Signal transduction 
The mammalian GPCR-ligand system is considered very complex. This complexity 
at the greatest part is determined by a large number of GPCRs majority of which are 
capable to bind more than one ligand and even larger number of ligands that are usually 
capable to bind to several GPCRs. This picture is becoming even more complex if the 
differential binding affinities are taken into account. However signal transduction system 
from receptor to heterotrimeric G-protein if far from less complex if compared to GPCR-
ligand system, although the number of GPCR activated Gα is significantly lower. There are 
several aspects of G-protein activation process that are increasing the complexity of signal 
transduction.  
There are two models proposed to explain the process of activated GPCR and G-
protein encounter process. The first, “collision coupling” model states that GPCR – G-
protein coupling occurs after activation of receptor and prior activation, receptor and G-
protein are freely diffunding in plasma membrane. (Tolkovsky et al. 1978) Second, 
recently developed, “precoupling” model on the other hand points that G-proteins can 
interact with the GPCR prior its activation and during ligand binding process G-protein is 
only being activated. (Gales et al. 2006) The latest of these two models could explain the 
rapid intracellular response that occurs after receptor activation, however it cannot explain 
the high level signal amplification, because according to scenario one receptor molecule 
activates only one precoupled G-protein molecule. Interestingly there are several studies 
that were carried out in the same GPCR – G-protein system, but results of which supported 
opposing models. (Hein et al. 2005) It is possible that both models are true, meaning, that 
some types of the receptors are predominantly precoupled while others are freely 
diffunding in plasma membrane and even more that some types of receptors are 
functioning under some kind of a mixed coupling model. 
As mentioned in previous section after the binding of the ligand receptor is 
changing its conformation creating the G-protein binding pocket, formed by intracellular 
parts of TM3 and TM7. The last 11 amino-acid residues of C-terminus (Kisselev et al. 
1998; Koenig et al. 2002) and amino-acid residues located in fourth α-helix and sixth β-
sheet (Bae et al. 1997; Onrust et al. 1997; Bae et al. 1999) are regions of Gα that are 
interacting with this binding pocket during G-protein activation process. Even more, there 
are reports that receptor and Gβγ complex interaction, at least in some cases, is also crucial 
for receptor and Gα interaction stabilisation. (Taylor et al. 1994; Taylor et al. 1996) The 
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complexity of these interactions is determined by the distinctive ways of how the various 
amino acid residues in various positions of described regions are contributing to receptor 
and G-protein coupling. It has been shown that not only complete exchange of C-terminus 
of Gα (Conklin et al. 1993) but also a simple two amino acid residue dissimilarity at near 
previously described interaction regions (Bae et al. 1999) can alter the specificity of 
receptor and G-protein coupling. This observation is also true regarding the GPCRs. In this 
case, since the 3D structure of the GPCRs is not as rigid as the structure of G-proteins, 
even changes that occurred spatially far from surfaces of interaction can have influence on 
coupling. Even more, beyond specificity of Gα, there are studies which reveal the coupling 
preference of some Gβγ complexes to specific receptors. (Hou et al. 2000; McIntire et al. 
2001) In fact all studies performed in this field, if taken together, reveal the existence of 
complex and tingled network of specificity defining interactions.  
Since there are more than 800 different GPCRs and only 21 Gα in mammalian 
organisms, it is clear that each Gα must be able to couple to more than one receptor. 
However some receptors have been identified that are able to couple with more than one 
type of Gα. Even more, this dual coupling is ligand dependant, meaning that choice of Gα 
depends on specific ligand, receptor is bound to. (McLaughlin et al. 2005; Mukhopadhyay 
et al. 2005; Perez et al. 2005) Existence of such dual action mechanism raises the 
complexity level of GPCR – G-protein signal transduction even higher.  
Coupling to activated receptor triggers the conformational changes in G-protein. As 
the result Gα subunit of G-protein opens the nucleotide binding pocket and exchanges its 
GDP for GTP. The exchange of nucleotide is rather passive process and mainly relies on 
excess of GTP concentration over GDP concentration in the cytoplasm of the cell. The 
exchange of nucleotide triggers further structural rearrangements as the result of which Gα 
adopts its active conformation and dissociates from the Gβγ complex and from the 
receptor. During the following phase of signal transduction active Gα and free Gβγ 
complex are acting as two separate proteins. While in its active conformation the Gα is 
able couple with its target protein, usually enzyme, like, adenyl-cyclase or protein kinase, 
but coupling to ion channels or other types of cell signal system proteins also occurs. This 
coupling activates the target protein, which in its turn alters the concentrations of 
intracellular secondary messenger molecules. The type of activated target protein depends 
on the type of Gα (Tab. 1) Since the Gα possesses GTPase activity, during the target 
protein activation the bound GTP is being slowly hydrolysed to GDP thus inactivating Gα. 
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After the inactivation Gα couples to Gβγ complex forming initial heterotrimeric G-protein. 
After disassociation from the Gα some types of Gβγ complex are also taking part in signal 
transduction. These are also coupling and activating their own target protein, that usually 
triggers concentration alterations of intracellular secondary messenger that is distinctive 
from one altered by its Gα. Since not all of the Gβγ complexes are capable to participate 
directly in signal transduction, the range of target proteins Gβγ can couple to is 
significantly lower (Tab. 1 Fig. 4) (Alberts et al. 2002). 
 
Figure 4. Panel (I) The disassembly of an activated G-protein into two signalling 
components. (A) In the unstimulated state, the receptor and the G protein are both 
inactive. Although they are shown here as separate entities in the plasma membrane, in 
some cases, at least, they are associated in a preformed complex. (B) Binding of an 
extracellular signal to the receptor changes the conformation of the receptor, which in 
turn alters the conformation of the G protein that is bound to the receptor. (C) The 
alteration of the α subunit of the G protein allows it to exchange its GDP for GTP. This 
causes the G protein to break up into two active components—an α subunit and a βγ 
complex, both of which can regulate the activity of target proteins in the plasma 
membrane. The receptor stays active while the external signal molecule is bound to it, 
and it can therefore catalyze the activation of many molecules of G protein. 
Panel (II) The switching off of the G-protein α subunit by the hydrolysis of its bound 
GTP. After a G-protein α subunit activates its target protein, it shuts itself off by 
hydrolyzing its bound GTP to GDP. This inactivates the α subunit, which dissociates 
from the target protein and reassociates with a βγ complex to re-form an inactive G 
protein. Binding to the target protein or to a membrane-bound RGS protein (not shown) 
usually stimulates the GTPase activity of the α subunit; this stimulation greatly speeds 
up the inactivation process shown here. (Figure and figure legend are from Alberts et al. 
2002) 
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Described above is the classical understanding of G-protein signalling, which, to 
date, is still true but highly simplified. Exclusions and control mechanisms for almost 
every step of this process have been identified.  
From functional point of view there are several types of ligands. Agonists are 
ligands that activate receptor; antagonists - ligands that are binding to receptor at the same 
binding pocket as agonists not activating the receptor and prohibiting agonists access to the 
binding pocket; inverse agonists that are inactivating constitutively active receptors (those 
usually have pharmacaphore fused to their N-terminus and do not have any agonists at all) 
positive allosteric modulators - ligands that are binding to receptor at the another-
secondary binding pocket (different from the one occupied by agonists and antagonists), 
enhancing the agonist binding or receptor activation efficiency; and negative allosteric 
modulators, that are binding to receptor at the another-secondary binding pocket, 
diminishing the agonists binding or receptor activation efficiency. As one can understand 
from these descriptions already at ligand binding stage there exists an elaborate control 
system. It should be mentioned that most of the receptors have no natural antagonist or 
allosteric modulator, however these ligands types are very extensively used in pharmacy. 
(Zheng et al. ; Bond et al. 2006; Wang et al. 2009) 
In previously described - classical understanding receptor is viewed as monomer, 
however the reality is quite different: large number of GPCRs is known to form homo and 
hetero oligomers, formation of which itself is a well known phenomenon. In the world of 
proteins, oligomerization has been recognized as advantageous from several aspects. Most 
obvious of these is the saving of space in the carrier of genetic material, for large proteins 
that are formed by number of identical subunits it is more convenient to store information 
of single domain in one - small gene, than store it in large gene encoding reputing multi-
domain protein or multiple genes encoding the same subunit. Homodimerization of two 
identical GPCRs allows them to act in trans on one another, meaning that, due to 
involvement of larger number of molecular interactions, which are “knitting” various parts 
of proteins together, from conformational point of view dimers are more rigid than 
monomers and because of this rigidness they, upon ligand binding, are changing their 
conformation more reluctantly, however, conformation changes of one partner are 
subsequently forcing the second to follow more rapidly. If compared graphically the 
activation curve of dimer would be steeper than activation curve of monomer, thus dimers 
would exhibit better “molecular on-off switch” properties. Another advantage that homo- 
or heterooligomerization of GPCRs could provide is additional regulation leverages. The 
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simplest is based on the fact that interaction of two GPCRs can stabilize both receptors in 
conformation that is more/less suitable for ligand binding, hence increasing/decreasing the 
receptor affinity for the ligand. In this case it is possible to regulate the sensitivity of 
receptors by the means of receptor concentration changes. However, usually regulations 
that involve oligomerization are more complex. Formation of GPCR-GPCR hetrodimer has 
been shown to result in changes of ligand binding or G-protein coupling profile. For 
example Dopamine D1 and D2 receptors expressed individually are coupling to Gsα and 
Giα respectively, while D1/D2 heterodimers are coupling to Gqα. When referring to 
heteromerisation it should also be kept in mind that the term includes not only 
oligomerization of different GPCRs but also formation of GPCR and other non-GPCR 
protein complexes. It has been established that number of GPCRs, require the presence of 
specific accessory proteins for the functional activity. (Klemm et al. 1998; Rios et al. 
2001; Millar et al. 2010) 
Desensitization and internalisation (or sequestration) of GPCRs are processes that 
also affect GPCR signalling. Main purpose of these processes is to inactivate GPCR, 
making the cell unresponsive, after reception of the initial signal thus prohibiting the 
unnecessarily continuous activation of intracellular signalling cascades and saving the 
resources of the cell. These processes are also crucial on the scale of whole organism, in 
remotely localized cell response synchronisation it allows the cells that receive the signal 
later to catch up with the ones activated earlier. Effects of desensitization and 
internalisation are usually reversible, shortly after inactivation receptors are reactivated and 
cell is again ready “for action”. Desensitization is relatively fast process, it often takes 
place immediately after activation of G-protein and runs in the time scale from few 
milliseconds up to few seconds. GPCRs are desensitizated by phosphorylation of their 
intracellular loops and/or C-terminus and subsequent coupling to arrestin, a soluble 
cytoplasm protein, which prohibits receptor coupling to G-protein. Phosphorylation is 
carried out by G-protein coupled receptor kinases (GRKs) which are activated by various 
elements of intracellular signalling cascades initiated by the receptor itself. Internalisation 
on the contrary is rather slow process and runs in the time scale from few seconds up to 
few minutes. It starts with the recruitment of clathrin by GPCR bound arrestin, further 
newly formed complex is moved to region of cell membrane called clathrin coated pit 
where it is endocyted and transported to intracellular compartments of the cell. (Fig. 5) 
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Figure 5. Molecular mechanisms involved in the GRK- and β-arrestin-dependent 
desensitization and internalization of GPCRs. GPCR activation leads to GRK-
dependent phosphorylation of intracellular serine and threonine residues that facilitate 
the translocation and binding of β-arrestin proteins to the receptor. β-arrestins, via their 
association with the β2-adaptin subunit of the AP-2 heterotetrameric adaptor complex, 
target GPCRs to clathrin-coated pits. In addition to their association with β2-adaptins, 
β-arrestins also bind clathrin. The GPCR is subsequently internalized via clathrin-coated 
vesicles. AP-2, AP-2 heterotetrameric adaptor complex; βArr, β-arrestin; H, hormone; 
P, phosphate group. (Figure and figure legend are from Ferguson 2001) 
After internalisation, there are two possible scenarios, receptor is ether 
dephosphorylated and recycled to membrane or ubiquitinated and assigned for degradation. 
The choice of scenario usually depends on the type of receptor. There are receptors that are 
actually signalling only once it their lifetime and there are receptors that are being 
constantly recycled. In fact there are receptors that are being constantly internalised even 
without any receptor activation. Such situation has been observed in cell types which 
require rapid return of the sensitivity to certain stimuli and constant receptor internalization 
is believed to provide supply of active “sensitive” receptors. (Fig. 6) 
Although internalisation usually terminates the signalling of GPCRs, there are also 
some exclusions. In previously described scenario desensitization and internalisation took 
place after disassociation of receptor-Gα complex, thus only receptor was internalised, 
however there are situation when ligand-receptor-Gα is so highly stable that it does not 
disassociate and constantly activates target enzyme. It has been observed that in such cases 
whole membrane bound signalling machinery is internalised forming constantly signalling 
cell structures called signalosomes or signalling endosomes, which have been detected to 
remain active for as long as 30 minutes. In conclusion it was recently discovered that there 
are distinct GPCR signalling pathways, involving extracellular signalling-regulated 
kinases, that are activated through receptor coupling to arrestin, (Ferguson 2001; Wolfe et 
al. 2007; Xu et al. 2007; Kovacs et al. 2009; Rosenbaum et al. 2009; Jalink et al. 2010) 
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Figure 6. β-Arrestin-dependent regulation of GPCR trafficking and the mechanisms 
involved in GPCR resensitization. Panel A, mechanism I: GPCR resensitization is 
achieved by the clathrin-dependent internalization of GPCRs to endosomes, and the 
receptors are subsequently dephosphorylated and recycled back to the cell surface (1). 
Alternatively, GPCRs that internalize with β-arrestin either dissociate from β-arrestin in 
the intracellular compartment, and are both dephosphorylated and recycled (2) or are 
retained within large core vesicles and/or are targeted for degradation in lysosomes (3). 
Panel B, mechanism II: resensitization of GPCRs that are internalized with β-arrestin 
bound and do not recycle is mediated by the mobilization of a reserve pool of 
intracellular receptors and/or de novo receptor synthesis in the Golgi apparatus. A, 
agonist; AP-2, AP-2 heterotetrameric adaptor complex; βArr, β-arrestin; P, phosphate 
group. (Figure and figure legend are from Ferguson 2001) 
1.1.4 Systematic and phylogeny of GPCRs 
First attempts to classify receptors of GPCR superfamily were undertaken soon 
after discovery of Rhodopsin, however it was only in 1994 when the first universal 
classification system was created. (Attwood et al. 1994) At that moment there were ~400 
identified GPCRs and it was established that although similar in their secondary structure 
alignment of amino-acid sequences of all known receptors presents no apparent over all 
similarity. For this reason Attwood and his colleague focussed upon identification of 
“fingerprints” that would be characteristic for specific groups of GPCRs. Such approach 
turned out to be very successful and as the result all GPCRs were divided six classes or 
clans: A, B, C, D, E, and F and a number of subclasses or subclans that were labelled with 
roman numbers. The main advantage of this system, besides effective division, was that it 
was designed to cover not only receptors found in mammalians but also GPCRs found in 
other forms of life, for example classes D, E and F that unite Fungal mating pheromone 
receptors, cAMP receptors and archaebacterial opsins respectively as well as subclass IV 
in class A that unites invertebrate opsin receptors. (Attwood et al. 1994) Although 
effective and in following years widely accepted “fingerprints” classification system had 
its opponents. Main arguments of opposition considered low amino-acid sequence 
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homology among different GPCRs and advisability of amino-acid sequence usage as main 
criteria of division. These researchers claimed that, due to low sequence homology, 
secondary structure similarity of GPCRs must be the result of molecular convergence and 
usage of bound ligands and location of binding pocket as main criteria of classification 
would much more informative (Bockaert et al. 1999; Qian et al. 2003).  
Nevertheless the search of the new classification system that would be based upon 
sequence comparison and phylogenetical analysis were continued and in 2003 Fredriksson 
and his colleagues (Fredriksson et al. 2003) succeeded in creating GRAFS classification 
system for all GPCRs found in human. In this system all human GPCR Pool is divided in 
five main families: Glutamate (formed by 15 receptors), Rhodopsin (formed 241 
nonolfactory receptors, and 460 olfactory receptors), Adhesion (formed by 24 receptors), 
Frizzled (formed by 24 receptors) and Secretin (formed by 15 receptors) receptor families, 
and the name designated to the classification system is formed by the first letters of 
receptor family names. Interestingly this study also confirmed the results gained from 
“fingerprints” classification because rhodopsin, secretin and glutamate receptor families 
are corresponding to classes A, B and C respectively, however adhesion and frizzled are 
not corresponding to any of the “fingerprints” classes. (Fig.7)  
 
Figure 7. Phylogenetic relationship between the GPCRs (TMI–TMVII) in the human 
genome. The tree was calculated using the maximum parsimony method on 1000 
replicas of the data set terminally truncated GPCR as described under Materials and 
Methods. The position of the rhodopsin family was established by including twenty 
random receptors from the rhodopsin family. These branches were removed from the 
final figure and replaced by an arrow toward the rhodopsin family analysis in Fig. 8. 
(Figure and figure legend are from Fredriksson et al. 2003) 
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Further, since the Rhodopsin receptor family was the largest, researchers decided to 
investigate it in detail and the results were very intriguing. Phylogenetical analysis 
revealed that receptors of this family are divided in four - distinct groups designated as: α, 
β, γ and δ. Even further three of these groups were formed by a number of clearly 
distinguishable receptor clusters. So α group was formed by prostaglandin, amine, opsins, 
melatonin and MECA (Melanocortin, Endothelial differentiation, Cannabinoid and 
Adenosin binding) receptor clusters, γ group was formed by SOG (Somatostatin, Opioid 
and Galanin), Melanin-concentrating hormone and Chemochine receptor clusters and δ 
group was formed by MAS-related (MAS1 oncogene receptor related), Glycoprotein, Purin 
and Olfactory receptor clusters. (Fig. 8) 
 
Figure 8. The phylogenetic relationship between GPCRs (TMI–TMVII) in the human 
rhodopsin family. The tree was calculated using the maximum parsimony method on 
300 replicas. The position of the olfactory cluster was established by including 17 
diverse random receptors from the olfactory cluster. These branches were removed from 
the final figure and replaced by an arrow toward the olfactory receptor cluster. (Figure 
and figure legend are from Fredriksson et al. 2003) 
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Interesting as it is from the classification point of view, this research also provided 
considerable evidence that all GPCRS are evolutionary related. However the question: why 
there is such low overall sequence similarity remained open. To resolve it Fredriksson and 
his colleagues generated a hidden Markov model (HMM) for every identified receptor 
family. Further they extracted TM domain parts of the model sequences and created 
separate alignments for each TM domain. Acquired results revealed that there are number 
of conserved motifs within various TM domains and although none of them is shared by all 
five families, each is connecting families in groups of two or more, which suggests that 
after split from common ancestor each family accumulated a set of family specific changes 
retaining only a small portion of ancestral sequence located in various regions, thus 
prohibiting similarity detection in large scale sequence comparisons. (Fredriksson et al. 
2003) 
Although very well built GRAFS classification system had one serious 
shortcoming: it was built on comparison of receptors found in only one organism. To 
compensate it authors in their further publication were focusing on receptors found in other 
fully sequenced organisms (Fredriksson et al. 2005). In this study they used previously 
generated HMMs and generated new ones for the groups of GPCRs that are not found in 
mammals, but are described in other classification systems. These HMMs were 
subsequently used to group all identified GPCRs of studied fully sequenced organisms into 
a families and the acquired results were intriguing. They revealed that all GPCR families 
arose prior the split of nematodes from chordate linage and that there are only few linage 
specific groups of receptors which led to conclusion that GRAFS classification is relevant 
in all analyzed bilateral species. Taken together they also highlighted the important role 
GPCR played during the evolution “higher species” (Fig. 9). (Fredriksson et al. 2005; 
Schioth et al. 2005) 
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Figure 9. Evolutionary tree with the number of GPCRs in different species indicated in 
graphs. The graph displays the logarithm of the number of GPCRs at the y-axis, with 
the main class above the x-axis and the subdivision of Rhodopsin GPCRs below the x-
axis (hatched). The numbers at the nodes indicate the time in millions of years since the 
split at that node occurred, taken from fossil data. (Figure and Figure legend are from 
Fredriksson et al. 2005) 
1.1.5 Intronless state of mammalian GPCR genes and intron evolution  
Rhodopsin GPCRs is one of the gene families in mammals with a large proportion 
of intronless genes (Brosius 1999; Gentles et al. 1999). This is very uncommon, since the 
overall density of intronless genes in human is only 12,3% (in other eukaryotic organisms 
varies from 2,7% in Caenorhabditis elegan to 97,7% in Encephalitozoon cuniculi). Usually 
the intronless state is an indicator that a particular gene family is undergoing active 
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changes and since the Rhodopsin GPCR family is very large this peculiarity, along with 
the facts that several of these receptors are recognized as ancient and that many groups 
have expanded at different stages of evolution, can be used to study the evolutionary 
history of introns. (Brosius 1999; Gentles et al. 1999; Sakharkar et al. 2004).  
Another interesting fact that makes this group attractive for studies is, that although 
many of Rhodopsin GPCRs in mammals are intronless, most GPCRs from invertebrates 
contain at least one intron. Previous studies have proposed explanations to this unevenness, 
leading to two different conclusions. The first: number of papers suggests that the low 
number of introns in mammalian GPCRs is related to gene multiplication through 
retroposition, which means that new genes are intronless (Brosius 1999; Gentles et al. 
1999). The second conclusion, which is quite controversial, suggests that there occurred a 
major loss of introns within the Rhodopsin GPCR family. It was argued that the majority 
of genes lost an “ancient” intron located in the conservative DRY motif of Rhodopsin 
GPCR (Bryson-Richardson et al. 2004). 
After the discovery of introns in 1977 (Berget et al. 1977; Chow et al. 1977; 
Jeffreys et al. 1977), there has been continuous discussion about the functions,  origin and 
time of origin of introns.  
Regarding the functions of introns in the cell it was only the question of careful 
practical research and it was not long before the answer giving discoveries started to come 
forth. At the present moment there are at least six identified functions of introns in the cell: 
introns are one of the sources of non coding RNAs, a source of regulatory elements and act 
in alternative splicing and trans-splicing. Introns also function as enhancers of meiotic 
crossing over within coding sequences, in exon-shuffling and as signals for mRNA export 
from the nucleus and nonsense-mediated decay (Fedorova et al. 2003).  
However the answers to questions concerning intron evolution are more difficult to 
obtain. In this field two main theories have been proposed. The “introns early theory” 
which states that introns as such must be very old formations that existed in common 
prokaryote and eukaryote ancestors, and that prokaryotes must have lost them during their 
evolution (Darnell 1978; Doolittle 1978; Gilbert 1978). As opposite is the “introns late 
theory” which proposes that introns must be a recent addition – selfish DNA, inserted 
through transposition and spread very quickly all over the genome of an ancient eukaryote 
before the split of the main eukaryotic lineages (Cavalier-Smith 1985). The latter theory 
was supported by Nicholas J. Dibb and Andrew J. Newman proposed the “proto-splice” 
site theory which states that conservative introns flanking MAG|R sequence (| - represents 
26 
the position of the intron, M represents A or C and R represents A or G) could serve as a 
signal for intron insertion (Dibb et al. 1989).  
Ever since the beginning of formation of these two contradicting theories there has 
been a large amount of papers from different groups that took a side of either opinion. 
Some of these papers were clearly theoretical, mostly stating arguments against one or 
another opinion (Cavalier-Smith 1985; Fedorov et al. 2004), while the vast majority were 
built on practical investigations of modern introns (Lee et al. 1991; Giroux et al. 1994; 
Figueroa et al. 1995; de Souza et al. 1996; Cho et al. 1997; de Souza et al. 1997; Gilbert et 
al. 1997; Hankeln et al. 1997; Long et al. 1998; O'Neill et al. 1998; Tarrio et al. 1998; 
Venkatesh et al. 1999; Long et al. 2000; Fedorov et al. 2001; Roy et al. 2002; Fedorov et 
al. 2003; Roy et al. 2003; Tarrio et al. 2003; Sadusky et al. 2004; Roy et al. 2005c; Roy et 
al. 2005a; Roy et al. 2005b) Eventually, during the last years, there has been a growing 
number of publications from authors that support the “mixed theory of introns”, which 
states that introns are extremely old formations, but some intron insertion is still occurring 
(de Souza et al. 1998; Roy et al. 1999; Roy et al. 2003). 
Gene duplication is another process that goes hand in hand with intron gain and loss 
and also might explain the intronless state of mammalian Rhodopsin GPCR genes. It is 
considered to play a crucial role in development and the evolution of life, even in the RNA 
world (Brosius 2003) and taken together fits very well in the evolution of mammals. 
According to Hurles review (Hurles 2004) duplication of gene before its alternation is 
crucial for survival, because every gene has its function and most of the changes are 
leading to inactivation, which in a case of one gene may cause death of organism, but in a 
case of two copies one, not necessarily the new copy, might become open for changes and 
in time acquire new function. It is certain, that the fastest way for organism to change is 
through modification of regulatory pathways, a specially the ones modifying metabolism in 
general and ones involved in organism development, from fertilized ovule to adult 
organism. And since the receptors are integral part of these regulatory pathways, the fact of 
their amplified duplication and specific evolution raises no surprise. There is another 
crucial thing. A newly arisen gene, that has been duplicated in a single genome must 
become fixed in the population and preserved over time before it can be observed in 
evolutionary comparisons. The explanation of how receptor and other genes have 
overcome these difficulties lies in the way of formation of new species. The main 
requirement for formation of new species is geographical or other isolation of the group of 
individuals, which, in a case of a small group, automatically leads to high level of 
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inbreeding and greatly raises the chance of any duplication to become fixed and preserved, 
if it is harmless or improving. (Hurles 2004) 
The gene duplication mechanisms through RNA intermediates is perhaps of most 
interest in this context since it is one of the oldest and originates from the time when 
modern life exchanged the carrier of its genetic material from RNA to DNA and it is also 
the one that involves intron loss. There are at least three other known single gene 
duplication mechanisms that are taking place in modern cells but they involve mechanisms 
connected with DNA rearrangement and whole gene (including introns) duplication. All of 
these mechanisms have been observed to happen with different frequency in different 
situations and they can appear at different stages of evolution (Danielson et al. 1999). A 
number of specific duplication events have been reported in different organisms and these 
can be lineage-specific and sometimes even species-specific (Lespinet et al. 2002). 
1.2 Melanocortin system 
The melanocortin system is involved in regulation of many different physiological 
functions, including the formation of pigmentation (De Wied et al. 1982; Spencer et al. 
2008), adrenocortical steroidogenesis (Simpson et al. 1988; Allolio et al. 1997; Chida et al. 
2007), energy homeostasis (Sina et al. 1999; Yeo et al. 2000; Lu 2001; Williams et al. 
2001; Ellacott et al. 2004; Butler 2006; Ellacott et al. 2007; Muceniece et al. 2007), 
exocrine secretion (Chen et al. 1997; Thiboutot et al. 2000), sexual functions (Argiolas et 
al. 2000; Wessells et al. 2000; Pfaus et al. 2004), inflammation and immunomodulation 
(Haycock et al. 1999; Starowicz et al. 2003; Muceniece et al. 2005; Lasaga et al. 2008), 
thermoregulation (Fan et al. 2005; Fan et al. 2007) and cardiovascular regulation 
(Humphreys 2004; Rinne et al. 2008). 
If looking from the functional point of view all elements of this system can be 
divided in three groups: signalling molecules (hormones) or melanocortins when referred 
to this system, melanocortin receptors that are located in the membrane of the cell and are 
interacting with signalling molecules thus transducting signal to interior of the cell, and the 
elements of this system that modify signalmolecule-receptor interaction. 
1.2.1 Melanocortin (MC) peptides  
Term “melanocortin” is referred to peptides originated from proopiomelanocortin 
precursor (POMC), which exhibits melanotropic and adrenocorticotropic activity. MCs are 
produced mainly in frontal and intermediate lobe of pituitary, Nucleus arcuatus and 
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Nucleus trectus siolitarii, however lower levels of production have been found in almost 
all organs. They are formed from three different POMC regions and they all share the same 
MC conservative -His-Phe-Arg-Trp- (-H-F-R-W-) sequence that serves as pharmacophore 
for melanocortin receptors (MCRs). (Eberle 1988) γ-melanocyte stimulating hormone 
(MSH) is formed from N-terminal part of POMC, adrenocorticotropic hormone (ACTH) 
and α-MSH are partially overlapping peptides and are formed from the central region of 
POMC. β-MSH, β-lipotropic hormone (LPH) and γ-LPH are all derivates of C-terminal 
part of POMC (Smith et al. 1988) (Fig. 10) 
Clear view on a wide variety of functions in regulating by melanocortins was 
acquired with description of the first two Caucasian children lacking products of POMC 
gene. Both patients displayed number of metabolism disorders as the result of 
hypocortisolaemia, both developed severe obesity caused by hyperphagia and both had a 
pale skin and red hair. (Krude et al. 1998) The designation of the last symptom, red hair, as 
POMC characteristic, however was placed under the question because in 2006 a child of 
the Turkish origin lacking POMC products, but retaining black hair, was identified. 
(Farooqi et al. 2006)  
α-MSH and ACTH are the most abundantly studied melanocortins and as 
previously mentioned these are overlapping peptides thus they share a significant sequence 
identity. These two peptides are the most studied melanocortins since they are mediating 
most of melanocortin system effects.  As the name of α-MSH suggests the first identified  
 
 
N-terminal fragment ACTH
-MSH -MSH -MSH -endorphin
-lipotropin
   

 
ACTH H2N-SYSMEHFRWGKPVGKKRRPVKVYPNGAEDESAEAFPLEF-OH 
α-MSH AC-YSMEHFRWGKPV-NH2 
β-MSH H2N-AEKKDEGPYRMEHFRWGSPPKD-OH 
γ-MSH YVMGHFRWDRFG-OH 
NDP-MSH AC-YSXEHZRWGKPV-NH2  
Figure 10. Schematical representation of proopiomelanocortin precursor (upper part) 
and Sequence alignment of melanocortin peptides (lower part). All melanocortins, 
except for NDP-MSH, are formed from various regions of proopiomelanocortin 
precursor. All of them share conservative His-Phe-Arg-Trp (HFRW) motif. NDP-MSH 
is synthetic analogue of α-MSH, X represents norleucine and Z represents 
D-phenylalanine. 
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function of this peptide was stimulation of skin pigmentation formation. In a skin, α-MSH 
is produced in keratinocytes in response to increased UV-radiation, it acts as local hormone 
and after release it is binding to the receptors on the surface of melanocytes thus 
stimulating the production of eumelanin. (De Wied et al. 1982; Bohm et al. 2005; Spencer 
et al. 2008) In central nervous system α-MSH, β-MSH, γ-MSH and ACTH are produced in 
frontal and intermediate lobe of pituitary. Here the α-MSH, β-MSH and γ-MSH are also 
acting as local hormones binding to receptors on the surface of neurons further actions of 
which cause inhibition of the food intake and regulation of energy homeostasis (Yeo et al. 
2000; Lu 2001; Williams et al. 2001; Harrold et al. 2003; Ellacott et al. 2004; Butler 2006; 
Ellacott et al. 2007) regulation of sexual functions (Argiolas et al. 2000), thermoregulation 
(Fan et al. 2005; Fan et al. 2007) and cardiovascular regulation (Humphreys 2004). ACTH 
on the contrary is being mainly released into the blood stream, and carried to adrenals 
where binding to its receptors is promoting the release of corticosteroids (Simpson et al. 
1988; Allolio et al. 1997; Chida et al. 2007). It should be also acknowledged that there are 
reports of melanocortins, in various parts of organism, playing a crucial role in 
imunomodulation and regulation of inflammation, (Haycock et al. 1999; Starowicz et al. 
2003; Lasaga et al. 2008) as well as regulation of exocrine secretion (Chen et al. 1997; 
Thiboutot et al. 2000) however the mechanisms involved in these functions at this point 
are unclear. 
1.2.2 Melanocortin receptors (MCRs) 
Using set of molecular cloning techniques at the beginning of the 1990s a new 
family of GPCRs was identified that were specifically binding melanocortin (melanotropic 
and adrecocorticotropic) peptides. Chronologically the first identified receptors were 
melanocyte stimulating hormone receptor (MSHR or MC1R) (Chhajlani et al. 1992; 
Mountjoy et al. 1992) and adrenocorticotropic hormone receptor (ACTHR or MC2R) 
(Mountjoy et al. 1992). Other three receptors, MC3R (Gantz et al. 1993a), MC4R (Gantz 
et al. 1993b) and MC5R (Gantz et al. 1994) were identified few years later and were 
named by the order of discovery, since at that time there were no information regarding 
their functions. 
On the level of amino-acid sequence all MCRs share 39-61% identity. Interestingly 
MC3R, MC4R and MC5R seems to be more related to each other sharing, 55-61% 
sequence identity, than to MC1R and ACTHR, sharing only 43-46% sequence identity. 
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The least similar in this group of receptors are MC1R and ACTHR sharing only 39% 
sequence identity. 
The MCRs are mainly acting through the Gsα subunit that is coupled to adenyl-
cyclase (Chhajlani et al. 1992; Mountjoy et al. 1992; Gantz et al. 1993a; Gantz et al. 
1993b; Gantz et al. 1994; Theodoropoulou et al. 2008), however there are also reports of 
MC3R acting through members of Gq/11α subunit family that are coupled to pathways 
involving phospholipase C-mediated hydrolysis of phosphoinositides and mobilization of 
intracellular Ca2+ (Konda et al. 1994). 
Although all MCRs are predominantly acting through same type of Gα subunit, 
they all are displaying unique pharmacological profile, binding various melanocortins with 
distinctive affinities (Tab. 2). In a way MC3R and ACTHR are the most specialized ones. 
MC3R is the only of MCR that among other melanocortins effectively binds γ-MSH and 
ACTHR is specifically binding only ACTH. It has recently been discovered that, besides 
the melanocortin conservative -H-F-R-W- motif, the second pharmacophore 
-Lys-Lys-Arg-Arg- (-K-K-R-R-), located in the central part of ACTH, is also required for 
the activation of ACTHR. (Kovalitskaia et al. 2008)  
As mentioned previously first identified MCRs were MC1R and ACTHR. The 
discovery of both receptors was accomplished in year 1992. Interestingly MC1R was 
discovered by two independent research groups that were led by Roger D. Cone and Jarl 
E.S. Wikberg (Chhajlani et al. 1992; Mountjoy et al. 1992), while ACTHR was discovered 
only by the Roger D. Cone’s research group (Mountjoy et al. 1992). Both groups were 
using the same degenerate primer PCR technique. Primers of both groups were targeted for 
conservative GPCR TM7 region, and the only difference in strategy lied in choice of 
template DNA. Cone’s research group used cDNA library acquired from Melanoma cells 
while Wikberg’s group used genomic DNA of Melanoma cells. 
At the present moment it is established that MC1R is predominantly expressed in 
melanocytes (Tab. 3) where it senses nanomolar changes of α-MSH concentrations and  
 
Table 2. The melanocortin system (Gantz et al. 2003) 
Receptor Potency of Ligands Antagonists Primary Functions 
MC1R α-MSH=ACTH>β-MSH>_-MSH Agouti Pigmentation, inflammation 
MC2R ACTH Agouti Steroidogenesis 
MC3R α-MSH=β-MSH=γ-MSH=ACTH Agouti, AGRP Energy homeostasis 
MC4R α-MSH=ACTH>β-MSH>γ-MSH Agouti, AGRP Energy homeostasis, erectile function 
MC5R α-MSH>ACTH>β-MSH>γ-MSH  Sebaceous gland secretion 
MC1R, melanocortin receptor-1; MSH, melanocyte-stimulating hormone;  
ACTH, adrenocorticotropic hormone; AGRP, agouti-related protein. 
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stimulates the formation of skin and hair pigmentation. Besides melanocytes its expression 
has also been detected in other types of tissues: keratinocytes, fibroblasts, endothelial cells, 
antigen-presenting cells and leukocytes, where it mediates the anti-inflammatory effects of 
melanocortines. (Gantz et al. 2003) 
At the beginning the naming of the newly identified receptor as adrenocorticotropic 
was quite controversial, because there were no direct evidences of particular GPCR and 
ligand binding only indirect indications, like sequence similarity with the MCRs and 
expression in the adrenal cortex, a tissue type known to express real ACTHR. The inability 
to gain a conclusive proof was mainly because of difficulties to gain a sound heterologous 
receptor expression in endogenous MCRs expressing cell lines. Thus results acquired, at 
that time, could not accurately characterise pharmacological properties of expressed 
protein.(Noon et al. 2002)  
The situation was changed in 1995 when Rong Qiu and his colleagues using the 
adrenal cell line Y1 created Y6 and OS3 cell lines lacking the endogenous MCRs 
expression. (Schimmer et al. 1995) However, the question regarding the reasons of such 
expression selectivity remained open. Further studies of this subject, performing 
comparison of ACTHR-GFP (Green fluorescent protein) fusion protein expression in CHO 
and Y6 cell lines showed that in all, but adrenal, cell lines this receptor is retained in 
endoplasmatic reticulum, which suggested that there exists some kind of ACTHR arrest 
signal, which is bypassed in adrenal cells. (Noon et al. 2002) After this study there were no 
significant advancements until 2005 when Matherell and his colleagues performing genetic 
analysis on a family with Familial glucocorticoid deficiency (FDG), identified 
Melanocortin receptor accessory protein (MRAP) - a small membrane protein which 
presence is necessary for ACTHR to successfully reach the cell plasmatic membrane. 
(Metherell et al. 2005) 
ACTHR is mainly expressed in zona reticularis and zona fasciulata of adrenal 
cortex and in adipocytes (Tab. 3) (Boston et al. 1996; Beuschlein et al. 2001) and up to  
 
Table 3. Expression and genomic localisation of all Melanocortin receptors 
Receptor Expression location Genomic Localization  
MC1R (MSH-R) 
MC2R (ACTH-R) 
MC3R 
MC4R 
MC5R 
Melanoccytes 
Adrenal cortex, adipocytes 
Hypothalamus, limbic system, placenta, digestive tract 
Hypothalamus, limbic system, cerebrum, brain steam 
Muscles, liver, spleen, lungs, barin, adipocytes... 
16q2 
18p11.2 
20q13.2 
18q22 
18p11 
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date it is the smallest identified GPCR. It consists only of 297 amino-acid residues with a 
total molecular weight of 33kDa (Mountjoy et al. 1992; Clark et al. 1996). In the adrenal 
cortex ACTHR mediates the effect of ACTH on glucocorticoid (Fig. 11)(Clark et al. 1996) 
and its own mRNA synthesis (Penhoat et al. 1989; Naville et al. 1999). In the mouse 
adipocytes it has been shown to play a role in lypolysis (Boston et al. 1996; Boston 1999), 
leptin (Norman et al. 2003) and interleukin 6 production (Jun et al. 2010), however the 
functions of ACTHR in human adipocytes has not been clarified yet. 
Genetic defects in ACTHR gene are causing Familial glucocorticoid deficiency 
(FGD) - a rare autosomal recessive disorder, which is characterized by low or undetectable 
plasma cortisol levels and an excess of plasma ACTH. It becomes apparent in childhood as 
frequent hypoglycaemia and/or infective episodes accompanied by excessive skin 
pigmentation. For all (FGD) patients that had the alterations in ACTHR gene, at least one 
of gene alleles was coding partially functional receptor, while the other one was frequently 
coding completely inactive receptor (Elias et al. 1999; Penhoat et al. 2002) 
Despite the already identified receptors, there were numerous evidences suggesting 
the existence of other high affinity MCRs in central nervous system (CNS) and other 
tissues besides the adrenal cortex and melanocytes. The authors of the time pointed that 
melanocortin peptides have a various effects upon cerebration, for example, memory 
(Sandman et al. 1969; Garrud et al. 1974), thermoregulation (Feng et al. 1987) etc. and  
 
 
Figure 11. ACTH Regulates the expression of certain adrenal steroidogenic enzyme 
genes as depicted in the boxes which catalyze the steps in glucocorticoid, 
mineralcorticoid and androgen synthesis as indicated. (Figure and figure legend are 
from: Clark et al. 1996) 
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there were also reports of high affinity MSH and ACTH binding sites in Lacrimal glands, 
CNS and peripheral tissues. (Tatro et al. 1987; Hnatowich et al. 1989; Tatro 1990; 
Salomon et al. 1993) 
Because of these evidences the searches for new MCRs were continued and as the 
result, using Northern Blot hybridisation method, the expression of a new - MC3R was 
detected in CNS and placenta. The cDNA of this receptor was acquired using reverse 
transcription from cells of stomach, duodenum and pancreas. (Gantz et al. 1993a) Further, 
using in situ hybridisation, it was established that mRNA of MC3R is transcribed in more 
than thirty nucleuses of rat CNS, mainly in hypothalamus and other structures of limbic 
system. (Roselli-Rehfuss et al. 1993) It is also notable that MC3R is only MCR which 
binds γ-MSH and receptor affinity for this ligand is close to affinity for other 
melanocortins. Further studies of this receptor determined that it is mainly involved in 
regulation of energy homeostasis. (Tab. 3) (Gantz et al. 2003) 
MC4R was discovered the same year as MC3R by the same group of researchers 
using the same set methods. (Gantz et al. 1993b) Detailed neuroanatomical in situ 
hybridisation mapping revealed that mRNA transcription of this receptor is wider spread 
than transcription MC3R mRNA. mRNA of MC4R was detected in almost every part of 
the brain - in ~148 different cerebral nucleuses including cerebral cortex, thalamus, 
hypothalamus, limbic system, brain stem and medulla (Tab. 3) (Mountjoy et al. 1994). As 
for the functions of this receptor, it was already known prior to MCR discovery that 
melanocortin peptides α-MSH and ACTH can influence the food intake of laboratory 
animals. (Panskepp et al. 1976; Poggioli et al. 1986) Later experiments with the synthetic 
nonselective MCR agonists and antagonists confirmed these observations. Laboratory Rats 
treated with the Malanoton II (synthetic agonist) displayed dislike for the offered food 
(Thiele et al. 1998) which was followed by delay of food intake (Fan et al. 1997). The 
treatment with the SHU9119 (synthetic antagonist) on the other hand increased the day, 
night and fastening induced food intake. (Fan et al. 1997; Kask et al. 1998c) It was also 
established that simple limitation of the access to the food decreased the transcription level 
of POMC coding mRNA in Nucleus arcuatus. (Brady et al. 1990; Kim et al. 1996) More 
detailed studies involving MC4R selective antagosnist HS014 revealed that treatment of 
laboratory rats with this substance induced severe food intake during the daytime. (Kask et 
al. 1998a; Kask et al. 1998b; Kask et al. 1998d) Taken together all these facts suggest that 
endogenous ligands of MC4R are food intake inhibiting signals which are preventing 
animal overeating through stabilisation of amounts of daily food intake. 
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The last identified receptor of this family was MC5R. It was discovered a year later 
by the group that identified previous two receptors. (Gantz et al. 1994) This is the most 
abundantly expressed MCR, the expression has been identified in muscles, thymus, spleen, 
ovary, testis, adrenal cortex, lungs brain and adypocytes. (Tab. 3) There is very little 
known about its functions and only detected anomaly of MC5R knock-out mice was the 
dysfunction of skin exocrine, especially sebaceous, glands. (Chen et al. 1997) 
1.2.3 Other elements of MC system 
Besides MCs and their receptors there are six other elements in MC system: Agouti 
signalling peptide (ASiP) (or Agouti in mice), Agouti related protein (AgRP), Mahogany, 
Syndecan-3, Melanocortin receptor accessory protein-α (MRAP-α), MRAP-β and MRAP2. 
Agouti and AgRP are paracrine signalling molecules. Currently they are the only 
identified endogenous GPCR antagonists, thus making MC system unique. Agouti is 
specifically binding to all MCRs except for MC5R while specific binding of AgRP is 
limited to MC3R and MC4R. Another specificity of these elements is that they are very 
large peptides, consisting of ~130 amino-acid residues. (Lu et al. 1994; Shutter et al. 1997) 
As the names of both proteins indicate Agouti was discovered prior to AgRP. (Lu et 
al. 1994) The name agouti comes from zoology where it is used for description of specific 
fur colour (yellow band on otherwise black or brown background) of various mammalians. 
Besides yellow fur colour agouti mice were tended to develop obesity, insulin resistance 
increased somatic growth and tumorogenesis. After discovery of its coding gene, it was 
noticed that all these effects are caused by widespread and unregulated expression of 
Agouti protein while in genetically healthy mouse its expression is limited to skin where it 
inhibits the action of α-MSH and ACTH on MC1R. (Gantz et al. 2003) Unlike Agouti the 
human homologue - ASiP is expressed in a broader range of cell types that includes: 
adipocytes, testis, ovary, heart, foreskin, kidney and liver (Wilson et al. 1995), but since 
the agouti hair colour has never been observed in humans its participation in formation of 
pigmentation is implausible, even more the question regarding the real functions of this 
protein in humans remains open. 
AgRP was discovered three years after Agouti. The coding sequence of this peptide 
was acquired thanks to the high level of sequence homology of both proteins. As 
mentioned above AgRP although similar to Agouti has a distinct pharmacological profile 
binding only to MCRs located in CNS. Besides differential pharmacology, the expression 
pattern of both proteins is also distinctive - AgRP is mainly expressed in nucleus arcuatus 
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that is located within the hypothalamus (Shutter et al. 1997). The expression of the shorter 
transcript (lacking the 5’ noncoding exon) has also been detected in adrenal cortex, testis, 
lung, kidney and dorsal root ganglia (Beltramo et al. 2003). The physiological role of 
AgRP in hypothalamus is to bind to adjacently localised MC3R and MC4R and inhibit 
their food intake suppressing action and thus stimulate the appetite (Ilnytska et al. 2008). 
Studies concerning the function of AgRP expressed in adrenal cortex have shown that, 
besides ACTHR and MC5R, minor amounts of MC4R and possibly MC3R are also being 
expressed in adrenal cortex were they are inducing cortisol release and, since AgRP is 
antagonist of these receptors, it might participate in regulation of cortisol release. It should 
be also mentioned, another theory regarding the action of AgRP in adrenal cortex states 
that there might also be other than MCRs high affinity binding sites for AgRP (Doghman 
et al. 2007). However there is very little or no knowledge about functions of AgRP when 
expressed in other parts of organism. 
Mahogany and Syndecan-3 are single pass transmembrane proteins that are 
believed to alter the activity of Agouti and AgRP respectively. Mahogany is mainly 
expressed in brain and skin, and it has been shown to be a low affinity receptor for Agouti 
but not AgRP. The idea that it might be part of MC system came from observation that 
mahadony mutation completely suppresses agouti caused fur colouring and health 
problems (obesity, insulin resistance, etc.) in mice. Knowing that Mahogany is only a low 
affinity receptor however, it is hard to explain such dramatic effect. Taken together with 
the discovery that Mahogany has its own, Agouti independent, effect on metabolic rate it 
leaves the question of its membership with the MC system open. Syndecan-3 is mainly 
expressed in the hypothalamus. Experiments involving Syndecan-3 coexpression with 
MC4R revealed the increasing efficiency of AgRP antagony. It has been therefore 
proposed that Syndecan-3 might act as AgRP coreceptor. This hypothesis however is also 
disputable since Syndecan-3 knock-out mice did not have any specific phenotype. (Gantz 
et al. 2003) 
The last three members of MC system are MRAP-α, MRAP-β and recently 
discovered MRAP2. All three are coupling to MCRs and, in the case of ACTHR, are 
promoting membrane transport or, in the case of other MCRs, inhibiting their functional 
activity. (Chan et al. 2009) All three MRAP’s are singe α-helical TM proteins. MRAP-α 
and MRAP-β are formed by alternative splicing from one gene. The gene is located in the 
locus 22.1 of the long arm of chromosome 21 (21q22.1), it is ~25Kb long and consists of 
six exons. 172 amino-acid isoform α is translated from mRNA formed by first five exons 
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of the gene while 102 amino-acid isoform β is formed from mRNA by third, fourth and 
sixth exons of the gene. Translation initiation codon is located in the third exon and TM of 
protein is encoded by fourth exon of the gene, thus both proteins have identical N-terminus 
and TM, but distinctive C-terminus. Analysis of expression patterns revealed that different 
types of tissues have differential preference for MRAP isoforms. Both subtypes are 
expressed in adrenals, testis, breast, ovary, adipocytes, skin and jejunum. MRAP-α alone is 
also expressed in thyroid, lymph nodes, ileum, liver, stomach and pituitary, while MRAP-β 
alone is expressed only in brain. (Metherell et al. 2005) Such diverse expression pattern of 
α and β isoforms might be explained by fact that ACTHR affinity for ACTH depends on 
coexpressed MRAP isoform (Roy et al. 2007). As mentioned previously MRAP2 was 
discovered quite recently, its gene is located in the locus 14.3 of the long arm of 
chromosome 6 (6q14.3), in total it consists of four exons and encodes 205 amino-acid 
protein. MRAP2 is expressed in brain and adrenals. (Chan et al. 2009) MRAP and MRAP2 
share relatively low 39% sequence homology in their N-terminal and TM region. Cross 
species studies of these proteins revealed two primate specific aspects of MRAP genetics. 
MRAP-β and first two exons (containing 5’UTR) are found only in this linage of 
vertebrates. Interestingly when all three proteins are compared with their respective 
homologues from other organisms there was a higher sequence similarity among MRAP2s 
than among MRAPs, which could indicate that MRAP2 more resembles the ancestral 
MRAP. (Chan et al. 2009; Webb et al. 2010) Regarding the mechanism of MRAP action, 
in recent few years a large number of important findings have been made. First major 
discovery, revealed that, in the cell, MRAP exists as a very stable, SDS resistant, 
homodimer. This by itself isn’t a unique case, because many membrane proteins, including 
GPCRs (Mandrika et al. 2010) are known to form dimers. The MRAP dimer however has 
the unique orientation of monomers - they are antiparallel, meaning that C-terminus of first 
monomer on the cytoplasmatic side of cell membrane while C-terminus of second on the 
extracellular side of cell membrane. (Sebag et al. 2007; Cooray et al. 2008) It was later 
reported that region formed by amino-acid residues 18 to 21 (-L-D-Y-L-),, located in N-
terminal tail, is crucial for ACTHR ligand recognition. Substitution of these amino-acid 
residues with alanine resulted in protein that promoted only the trafficking of receptor to 
plasma membrane but not signalling. This observation was also supported by the fact that 
ACTHR complex with MRAP2, which lacks this region, but is able to couple to ACTHR 
and promote its transport to cell membrane, displayed no functional activity. (Sebag et al. 
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2009; Webb et al. 2009) These studies also revealed that region formed by amino-acid 
residues 31 to 37 (-L-K-A-N-K-H-S-), located in adjacently to N-terminal part of TM 
region, is important for MRAP to form antiparallel dimmers. Removal of this domain 
resulted in formation of protein which N-terminus is always located on the extracellular 
side of the cell membrane. At the present moment it is believed that during translation of 
MRAP molecule it is always inserted into the membrane with its N-terminus located inside 
the lumen of endoplasmatic reticulum, however the previously mentioned TM N-adjacent 
region is making this orientation somewhat unstable and part of the molecules are 
swapping to alternative one. It is possible that this swapping continues on until the 
antiparallel dimer is formed. (Sebag et al. 2009) The last, but not least, of these major 
discoveries revealed that TM domain of MRAP is responsible for specific coupling to 
ACTHR, although the nature of this interaction at the present moment is unclear. (Sebag et 
al. 2009; Webb et al. 2009) In the conclusion it should be mentioned that previously 
described wide expression of all types of MRAP could indicate that this protein is also 
participating in regulation of other functions, outside melanocortin system. (Hinkle et al. 
2009; Webb et al. 2010) 
1.3 Chimerical proteins: prospects of application 
Directed modification of proteins, in order to improve or modify their 
characteristics is one of most important goals of biotechnology. Even more, this also is 
very useful tool to study protein biochemistry. Today in vitro DNA synthesis and 
recombinant DNA technology have made it possible to synthesize virtually any type of 
polypeptide, leaving only one question: what protein do we want to synthesize? There are 
two types of directed modification: formation of large random mutation libraries or 
modification through exchange of various regions of protein with other already existing 
ones. As stated by Nixon and his colleagues these regions might be individual amino-acid 
substitutions (point mutations) as well as secondary structure domains or whole subunits. 
(Nixon et al. 1998) Usually when it is needed for the resulting protein to be with the same 
functional properties, but with altered physical parameters, substitution of individual 
amino-acids or domains with homologue regions from other-similar proteins are applied. 
However when working with the chimerical proteins it should be kept in mind that 
introduction of large scale changes might disrupt the network of complex interactions, thus 
rendering acquired protein in functionally inactive state. Taking in to an account this 
information, introducing of point mutations might seem to be a safer way to go, however it 
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should be noted that exchange of defined structural domains to homologue structural 
domains can be successfully implemented without the loss of protein functional activity. 
(Beguin 1999) 
Although complex in theory, creation of chimerical proteins have been successfully 
applied to create new chimerical restriction enzymes (Chandrasegaran et al. 1999). 
Regarding receptors this method has been used to identify functions of specific domains or 
to identify domains responsible for specific functions, for example to determine domains 
of VPAC receptor that are responsible for binding with calcium effector (Langer et al. 
2002), or to identify which parts of D1B receptor are involved in signal transduction 
(Tumova et al. 2003). This approach has also been successfully implemented in studies of 
MCRs. In this way domains of MC3R and MC4R that determine distinctive coupling 
efficiency to G-protein were determined (Kim et al. 2002), domains of MC1R and MC3R 
that are involved in ligand binding (Schioth et al. 1998), domains of MC3R that determine 
receptors specific affinity for γ-MSH (Oosterom et al. 1999), as well as domains of MC4R 
that are involved of receptor binding with AgRP (Yang et al. 1999). 
Also it should not be forgotten that fluorescent proteins are also often fused with 
the protein of interest. The purpose of such fusion is to measure the expression levels, 
localisation in cell, co-localisation, concentration or other parameters of studied protein. 
1.4 Fluorescent proteins 
At the present moment the most abundantly used fluorescent protein is green 
fluorescent protein (GFP), which was initially acquired from in northwest Pacific Ocean 
living jellyfish Aequorea victoria. Aequorea victoria GFP is 238 amino-acids long protein 
that, while absorbing blue light (maximal absorption at 395 and 475 nm), emits green light 
(maximal emission at 509 nm), it is very resistant to cell proteases, provides stable 
fluorescence, doesn’t photobleach for at least 10 minutes and most importantly it doesn’t 
require any special cell cofactors to retain full functionality. (Chalfie et al. 1994). 
X-ray crystallography analysis of GFP that was carried out in 1996 revealed that its 
structure visually resembles 42Å high “barrel”, with 24Å diameter. This barrel like 
structure is formed by 11 parallel, almost ideal cylinder forming, in helix twined β-sheets. 
Chromophore - p-hydroxybenzylidene-imidazolidone, which is formed by cyclization of 
Ser65 and Gly67 and oxidation of α-β bond of Tyr66, is located within the α-helix at the 
centre of this “barrel”. (Fig. 12 and 13) This structure of β-sheets enclosed chromophore is 
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determining the high resistance of GFP to proteases and other agents of environment, 
because most of proteases are unable to cleave β-sheets and their barrel-type placement 
serves as the barrier, preventing influence of various chemical agents on action of 
chromophore. (Ormo et al. 1996) 
After its discovery number of research groups started to improve the properties of 
GFP. One of the first was attempt to reduce its molecular mass, however it turned out to be 
unsuccessful. It was established that GFP can be truncated only by one amino-acid from 
N-terminus and 10 to 15 amino-acids from C-terminus before losing its fluorescence 
ability. Further attempts of improvement included introduction of point mutations. Results 
acquired from these studies can be divided in two groups: mutations that influence the 
relative proportions of absorbance peaks and mutations that shift absorption and emission 
spectra.  
  
Figure 12. Schematically depicted 3D structure of GFP   
(a) β-sheet structured regions are coloured in -  , α-helix structured regions are 
coloured in -   and unstructured regions are coloured in -    
(b) chromophore - p-hydroxybenzylidene-imidazolidone is coloured in -   and to 
chromophore proximal amino-acids: Ser65 and Gly67are coloured in -    
Images were created using OpenRasMol software (Bernstein 2000) and structure 
published by Ormo and colleagues (Ormo et al. 1996) 
40 
 
Figure 13. Formation of GFP chromophore - p-hydroxybenzylidene-imidazolidone. 
(Image from Cubitt et al. 1995) 
The most striking examples of changes in relative proportions of absorbance peaks 
are mutations Thr203→Ile and Glu222→Gly, that are simplifying absorption spectra to one 
peak 395 and 475 nm respectively, and Ile167→Thr that inverts the absorption peak 
intensities of native GFP 
Most of at the present moment identified absorption and emission spectra shifting 
mutations are located in chromophore proximal amino acids. (Tab. 4) 
Exchange of the central tyrosine (Tyr66) with other aromatic amino-acid (Trp, His 
or Phe) results in shift of absorption and emission spectra to shorter wavelength. Because 
of it’s only slightly shifted absorption and greatly shifted emission, fluorescent protein 
with Tyr66→His mutation has been designated the name of blue fluorescent protein (BFP). 
However Despite these intriguing results all Tyr mutants had one common flaw – 
significantly lower fluorescence level. (Cubitt et al. 1995)  
It was also established that Ser65 exchange for Cys, Leu, Val or Ala resulted in loss 
of 395 nm 475 nm absorption peak and shift of 475 nm absorption peak to slightly longer 
wavelengths. Fluorescent protein with the greatest shift of absorption and emission peaks 
to longer wavelength formed with introduction of mutation Ser65→Thr. This mutant 
possessed three excellent properties: its emitted fluorescence was six times greater, its 
photobleaching was significantly slower and oxidation of its Tyr66 α-β bond, during 
formation of chromophore, was four times faster. (Cubitt et al. 1995) 
Based on these observations several research groups tried to improve the properties 
of GFP and its colour derivatives. Some of the improvements included attempts to 
maximize the expression yield of properly folded fluorescent proteins while others 
included attempts to improve properties involving efficiency and stability of fluorescent 
proteins. First approach, for example, was used by Yang and his colleagues, they created 
synthetic EBFP (Enhanced blue fluorescent protein) gene sequence containing codons 
preferentially found in highly expressed human proteins, additionally they introduced four 
point mutations (Phe64→Leu, Ser65→Thr, Tyr66→His, and Tyr145→Phe) in order to 
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optimize the expression of protein. (Yang et al. 1998) Second approach was used by 
several groups. Cormack and his colleagues and Mena and his colleagues created a 
libraries of random point mutations in region adjacent to chromophore of GFP and BFP 
respectively. Afterwards members of both groups selected those mutants that presented 
improvement in stability and fluorescence intensity. As the result Cormack acquired 
Phe64→Leu and Ser65→Thr mutations containing EGFP (Enhanced green fluorescent 
protein), that had 30 fold greater fluorescence intensity than native GFP (Cormack et al. 
1996) and Mena acquired Phe64→Leu, Val150→Ile, Val150→Ile and Val224→Arg mutations 
containing Azurite, that had 1.6 fold increased quantum yield and 40 fold reduced 
photobleaching (Mena et al. 2006). 
Table 4. The effect ov mutations within the chromophore region of GFP (Table and legand are from Cubitt et 
al. 1995) 
Ser65 mutations  Absorption max (nm) 
Emission max 
(nm) 
 Tyr66 mutations  Absorption max (nm) 
Emission max 
(nm) 
Native GFP 
Ser65→Ala 
Ser65→Cys 
Ser65→Leu 
Ser65→Thr 
395/475 
−/471 
−/479 
−/484 
−/488 
508, 503 
−/504 
−/507 
−/510 
−/511 
 Natīvais GFP 
Tyr66→Phe 
Tyr66→His 
Tyr66→Trp 
 
395 
360 
382 
436 
 
508 
442 
448 
485 
 
For Tyr66 mutants 475 nm absorption peak was very low and was considered as insignificant.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Suggested literature to gain basic understanding on the subject of the Doctoral thesis: 
Fedorova et al. (2003), Dibb (1993), Logsdon et al. (1998), de Souza et al. (1998), Tuteja 
(2009), Jalink et al. (2010), Millar et al. (2010), Fredriksson et al. (2003), Schioth et al. 
(2005), Gantz et al. (2003), Cone (2006), Webb et al. (2010) 
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2 MATERIALS AND METHODS 
2.1 E. coli stain 
DH5alfa - F-, phi80dlacZDelta M15, Delta(lacZYA-argF), U169, deoR, recA1, hadR17(rk-, mk+),gal-, 
phoA, supE44, Lambda-, thi-1, gyrA96m relA1. 
2.2 Mammalian expression cell lines 
HEK 293 (EBNA) - Human Embryonic Kidney cell line (Invitrogen) 
BHK – Baby Hamster Kidney cell line (Invitrogen) 
2.3 DNA agrose gel electrophoresis 
DNA agrose gel electrophoresis was carried out in TAE buffer (40 mM Tris-acetate pH 8,3, 20 mM Sodium 
acetate, 1 mM EDTA) 1,2% agarose (Fermentas, #R0491) gel with ethidium bromide to final concentration 
1µg/ml added. 
2.4 DNA fragment purification and extraction from agarose gel 
For all DNA gel extraction and purification steps Silica Bead DNA Purification and Gel Extraction Kit 
(Fermentas #K0513) was used. 
2.5 Plasmid DNA extraction 
Bacterial cells acquired from single colony or frozen stock were inoculated in 6ml (miniprep) or 150 ml 
(midiprep) of 2xYT media (16 g/l Bacto tryptone, 10 g/l Bacto yeast extract and 5 g/l Sodium chloride) with 
ampicillin added to final concentration 1mg/ml and incubated for 16-24h at 37ºC with aeration (~200rpm). 
For miniprep DNA extraction GeneJet™ Plasmid Miniprep Kit (Fermentas #K0503) was used and for 
midiprep DNA extraction JETSTAR 2.0 Plasmid Midiprep Kit (Genomed #210050) was used 
2.6 Preparation of transformation competent E. coli cells 
Bacterial cells acquired from single colony or freezed stock of desired stain were inoculated in 6ml of LB 
media (10 g/l Bacto tryptone, 5 g/l Bacto yeast extract and 10 g/l Sodium chloride) with no antibiotics added 
and incubated for 16-24h at 37ºC with aeration (~200rpm). ~1ml from overnight culture was inoculated into 
150ml of Psi broth (20 g/l Bacto tryptone, 5 g/l Bacto yeast extract, 5 g/l magnesium sulphate and pH 7,6 was 
adjusted using potassium hydroxide). The volume of overnight culture was scaled up or down as needed so 
the result was 0,03 ≤ OD590 ≤ 0,04 and incubated at 37ºC with aeration (~200rpm) till OD590 = 0,3 - 0,4. 
Further culture was incubated on wet ice for 15min and transferred to two precooled 50ml centrifugation 
tubes afterwards Cells were pelleted for 5min at 3220×g. Supernatant was discarded and 20ml of TfbI 
(30mM potassium acetate, 100mM rubidium chloride, 10 mM calcium chloride, 50mM magnesium chloride, 
15% v/v glyserol and pH 5,8 was adjusted using acetic acid) were added to each tube. Pelleted cells were 
resupended, incubated on wet ice for 15min and pelleted repeatedly for 5min at 3220×g. Supernatant was 
discarded and 2ml of TfbII (10mM MOPS, 75 mM calcium chloride, 10mM rubidium chloride, 15% v/v 
glyserol and pH 6,5 was adjusted using sodium hydroxide) were added to each tube. Pelleted cells were 
resupended, incubated on wet ice for 15min, quick-freezed in liquid nitrogen in 100µl aliquots and stored in 
at least -70ºC 
2.7 PCR directed mutagenesis 
For creation of mutant receptor genes Overlapping ends PCR directed mutagenesis approach was applied. 
During the first stage of the process following reaction mix was prepared in two microcentrifuge tubes: 5μl 
of 10× amplification buffer, 1μl of 10 mM dNTP Mix, 5μl of 10μM mutant DNA primer Fw or Rs, 5μl of 
10μM standard DNA primer Rs or Fw, 1μl of DNA of interest, 1μl (~4u) of Pfu DNA Polymerase 
(Fermentas, #EP0509) and MiliQ water up to 50.μl. Afterwards the tubes were placed in thermal cycler and 
after 2min of predenaturation at 95ºC, 40 cycles of following conditions were applied: Denaturation, 15s at 
95ºC, Annealing, 15s at tº that depended on each primer pair individually (usually ~55ºC), Synthesis, 1min 
72ºC. After the last cycle additional step of Synthesis was applied: 7min 72ºC. Prior the next reaction both 
43 
products were purified from remainder of PCR primers using agarose gel electrophoresis and extracted from 
acquired slices of gel. During the second stage of the process ollowing reaction mix was prepared: 5μl of 
10×amplification buffer, 1μl of 10 mM dNTP Mix, 5μl of 10μM standard DNA primer Fw, 5μl of 10μM 
standard DNA primer Rs, 2,5μl of both in previous stage amplified PCR products, 1μl (~4u) of Pfu DNA 
Polymerase (Fermentas, #EP0509) and MiliQ water up to 50μl. Afterwards the tube was placed in thermal 
cycler and after 2min of predenaturation at 95ºC, 40 cycles of following conditions were applied: 
Denaturation, 15s at 95ºC, Annealing, 15s at 55ºC, Synthesis and 1min 72ºC. After the last cycle additional 
step of Synthesis was applied: 7min 72ºC. Acquired PCR product was purified and its quality was tested by 
agarose gel electrophoresis. 
2.8 Restriction of DNA 
For restriction of DNA the following reaction mix was prepared: 2μl of 10×appropriate restriction buffer 
(restriction buffer Fermentas #BR5, restriction buffer G Fermentas, #BG5), 5-18µl of DNA (volume 
depended on type and concentration of DNA), 0,5µl of each of required restriction enzymes (HindIII 
Fermentas, #ER0501 or XhoI Fermentas, #ER0691 or BamHI Fermentas, #ER0051), and MiliQ water up to 
50μl. The reaction mix was incubated for 1h at 37°C. 
2.9 Ligation of DNA fragments 
For ligation of DNA fragments following reaction mix was prepared: 1µl of 10×ligation buffer, 1µl of 10mM 
rATP, 1µl of Vector DNA, 7µl of Fragment DNA, 1µl of T4 DNA ligase (Fermentas, #EL0011). The 
reaction mix was incubated overnight at 22°C. 
2.10 Transformation of E. coli cells 
Stock of transformation competent E. coli cells was removed from freezer (≤ -70°C) and thawed on wet ice. 
10μl of ligation mix or 1μl of plasmid solution was added afterwards tube was incubated on wet ice for 30 
min. The cells were heat shocked for 45 s at 42°C after which incubated on wet ice for 2 more min. Further 
the cells were transferred to 0,9ml of prewarmed LB (10 g/l Bacto tryptone, 5 g/l Bacto yeast extract and 10 
g/l Sodium chloride) media with no antibiotics added, incubated for 1h at 37ºC with aeration (~200rpm) and 
pelleted for 5min at 800×g. Most of supernatant was carefully discarded leaving ~100 μl of media. Cell pellet 
was then resuspended in this remainder and spread on pre warmed media-LB agar (10g/l Bacto tryptone, 5g/l 
Bacto yeast extract and 10g/l Sodium chloride, 15g/l Bacto agar, ampicilin 1mg/ml) plate. 
2.11 Sequencing of DNA 
For sequencing of DNA following reaction mix was prepared: 2μl of 5×amplification buffer (400mM TrisCl 
pH 9.0, 10mM MgCl2), 1µl of BigDye® Terminator v3.1 Mix (Applied Biosystems), 1µl of 5µM DNA 
sequencing primer, 1µl of matrix DNA and 5µl MiliQ water. Afterwards the tubes were placed in thermal 
cycler and after 1min of predenaturation at 96ºC, 35 cycles of following conditions were applied: 
Denaturation, 10s at 96ºC, Annealing, 10s at 52ºC and Synthesis, 4 min 60ºC. After end of reaction DNA 
from reaction mix was precipitated by addition of 1µl of 7,5M ammonium acetate and 30µl of 96% ethanol. 
Sample was vortexed, incubated at room temperature for 10 min and centrifuged for 15min at 20000×g. 
Supernantant was carefully discarded and 50µl of 70% ethanol were added. Then sample was repeatedly 
centrifuged for 5min at 20000×g, supernantant was carefully discarded and pellet was air-dried at 55ºC for 10 
min. 
2.12 Transfection and cultivation of mammalian expression cell lines 
2.12.1 Creation of semi-stable HEK 293 EBNA cell lines for cAMP and binding 
assays 
70μl of OptiMEM (Gibco/Invitrogen, 31985-047) media were transferred to sterile tube and 20μl of FuGENE 
(Boehringer Mannheim, Germany) transfection reagent were added directly to OptiMEM media and the mix 
was incubated in the room temperature for 5min. In another sterile tube 7μg of plasmid DNA and up to 30μl 
of OptiMEM media were mixed, then FuGENE containing mix from the first tube was transferred to second 
by direct pipeting into the solution. Combined mix was transferred by dripping into media (Dulbecco 
modified Eagle media (DMEM) (Gibco/Invitrogen, 31331-028), with 10% Fetal calf serum (FCS) 
(Gibco/Invitrogen, 10270-106), 250μg/ml geneticin (Gibco/Invitrogen, 10131-027), 100U/ml penicillin, 100 
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μg/ml streptomycin (Gibco/Invitrogen, 15140-122) and 25μg/ml Amphotericin B (Gibco/Invitrogen, 15290-
026)) of mammalian cell culture containing 100mm petri plate and the cell culture was incubated for 24h in 
CO2 incubator (37ºC, 5% CO2). Ater this period the Hygromycin B (Invitrogen, 10687-010) was added to 
final concentration 200 μg/ml and the cell culture was cultivated for ~3 weeks, during which every 48 h 
culture media was replaced and Hygromycin B added. 
2.12.2 Transfection of BHK cells for confocal microscopy 
1 μg of plasmid DNA was diluted in 100 μl of serum-free DMEM (with, 100 U/ml penicillin, and 100 μg/ml 
streptomycin) and 2 μl of TurboFect™ (Fermentas, #R0531) were added to the diluted DNA. Acquired 
solution was incubated for 15-20 minutes at room temperature and evenly distributed on the bottom of well 
of a 24-well plate containing Ø12mm microscopy cover slip. 1 ml of ~105 BHK cells was gently layered top 
of the TurboFect™/ DNA mixture and cells were incubated at 37°C in a CO2 incubator for ~24h prior 
microscopy analysis. 
2.13 cAMP response assay 
2.13.1 Stimulation 
H3 labelled adenosine (Amersham Pharmacia Biotech, TRK343) was added to cell culture containing petri 
plate to final concentration 5 µCi/ml (50µl of adenosine for 10ml of media) and cell culture was incubateded 
at 37°C in a CO2 incubator for 2h. For the first dilution in a suitable tube ligand: NDP-MSH (Neurosystem 
France) or ACTH (Neurosystem France) was diluted with Basal buffer (137mM NaCl, 5mM KCl, 0,44mM 
KH2PO4, 4,2mM NaHCO3, 1,2mM MgCl2, 20mM TES, 1mM CaCl2, 10mM glikoze, pH7,4) to the final 
volume of 150μl and concentration that exceeded the required three times. 100μl of Basal buffer were added 
to another nine tubes and a certain amount of ligand mix, that depended necessary step of dilution, from the 
first tube was transferred to the next one, the mix in the second microcentrifuge tube was thoroughly mixed 
and the same amount as before was transferred to next microcentrifuge tube, and so on until all ligand 
dilutions were prepared. 50μl of all dilutions were transferred to 96-well plate in two replicates and 50μl of 
pure Basal buffer were added to each well. For the negative and positive control 100μl of pure basal buffer 
and 100μl of 15μM forskolin in basal buffer respectively were added to separate wells in two replicates. The 
plate then was stored at 37ºC until needed further. H3 adenosine labelled cells containing petri plate was 
removed from CO2 incubator, media discarded, cells rinsed down with 5ml of Basal buffer, transferred to 
centrifuge tube and pelleted for 5min at 130×g. Supernantant was carefully discarded and cell pellet gently 
resuspended in 1100μl of Basal buffer with 0,5 mM IBMX. The Cell suspension was incubated at 37°C for 
10min and then 50 μl of it were added to every well of previously prepared 96-well plate. After 10min 
incubation at 37°C cells were pelleted for 2min at 1260×g and supernantant was discarded. Finally 200μl of 
0,33M percloric acid were added to every well, the plate was covered with parafilm and freezed. 
2.13.2 Chromatography 
Prior chromatography Dowex columns (Poly-Prep chromatography columns (BIO-RAD, 731-1550) filled 
with AG 50W-X8 Resin (BIO-RAD, 142-1451)) were equilibrated by applying 2×10ml of H2O and Alumina 
columns (Poly-Prep chromatography columns (BIO-RAD, 731-1550) filled with Aluminium oxide (Sigma, 
A-9003)) were equilibrated by applying 8ml of 0,1M imodazole (Sigma, I-0125) solution. Previously 
prepared reaction plate was thawed and centrifuged for 10min at 1260×g. Supernatant from each well was 
transferred to separate Dowex column and as the control 750μl of 0,33M percloric acid - 650cpm/ml 14C-
cAMP (Amersham Pharmacia Biotech, CFA442) solution were added to each column. Then columns were 
eluted with 2ml of H2O and the flow through was collected in scintillation vials that were supplemented with 
4ml of scintillation cocktail Optiphase HiSafe 3 (PerkinElmer, 1200-437). Dowex columns were placed upon 
Alumina columns and eluted once more with 10ml H2O (flow through was not collected). After sample 
transfer from Dowex, Alumina columns were eluted with 4ml of 0,1M imodazole solution. and the flow 
through was collected in scintillation vials that were supplemented with 7ml of Optiphase HiSafe 
3scintillation cocktail. In order to estimate efficiency of each column pair the control containing 750 μl of 
0,33M percloric acid - 650 cpm/ml 14C-cAMP solution and 2ml scintillation cocktail Optiphase HiSafe 3 was 
added to three separate scintillation vials. Finally for all samples in all scintillation vials 3H and 14C emission 
was measured. 
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2.14 Binding assay 
2.14.1 Preparation of membranes 
Cells in culture containing petri plate were washed down using media, transferred to centrifugation tube and 
pelleted for 4min at 340×g. Supernatant was discarded, cell pellet resuspended in 200μl pf BB buffer (25mM 
HEPES pH7,4, 2,5mM MgCl2, 1mM CaCl2) and transferred to microcentrifuge tube. Then cell suspension 
was homogenized for 40s using Jankie&Kunkel IKA-WERK Ultra-Turrax Homogenizer and 450μl of BB 
buffer were added to homogenizate. Resulting solution was centrifuged for 3min at 160×g and supernatant 
was carefully transferred to clean microcentrifuge tube and repeatedly centrifuged for 20min at 20000×g. 
Supernatant was discarded, pellet was resuspended in 400μl of BB buffer and the membrane suspension was 
homogenized once more for 10s. 
2.14.2 Binding and transfer to separation filters 
For the first dilution in a microcentrifuge tube the ligand was diluted with the BBB buffer to the final volume 
of 100μl and concentration that exceeded the required four times. Choice of variable ligand depended on the 
type of assay non labelled ligands (NDP-MSH or ACTH) were used for competition binding assays while 
radioactively labelled ([125I]-NDP-MSH (Euro Diagnostica)) was used for total binding assays. 100μl of BB 
buffer were added to another 11 microcentrifuge tubes and a certain amount of ligand mix, which depended 
on necessary step of dilution, from the first microcentrifuge tube was transferred to the next one, the mix in 
the second microcentrifuge tube was thoroughly mixed and the same amount as before was transferred to 
next microcentrifuge tube, and so on until all ligand dilutions were prepared. The following mix was 
prepared in two replicates for each dilution: 25μl of diluted ligand, 25μl of 0,6nM [125I] NDP-MSH, for 
competition binding assay or BBB buffer for total binding assay and 50μl of membrane suspension. 
Incubation in room temperature for 3 h was terminated by transfer of binding mix to 0,3% polietilenamine 
saturated GF/C Filtermat A filter (Wallac Oy, Turku, Finland) using TOMTEC Mach III cell harvester 
(Orange, CT, USA). After transfer filter was dried for 5 min at 60°C, and MeltiLex A scintillation sheet 
(Perkin Elmer) was melted-on. Measurement of β-radiation in each position was carried out using Wallac 
1450 automatic scintillation counter (Perkin Elmer). 
2.15 Preparation of confocal microscopy samples 
24h after transfection cell growth media was removed and coverslip was rinsed with 1ml 1×PBS (137mM 
NaCl, 2,7mM KCl, 8,1mM Na2HPO4, 1,5mM KH2PO4, pH7,4) buffer solution. 100μl of AlexaFluor® 633 
labeled wheat germ agglutinin (AF-WGA) (Molecular Probes-Invitrogen)/PBS solution were placed upon the 
coverslip and incubated for 2min at 37ºC. After removal of AF-WGA/PBS solution coverslip was rinsed with 
1ml 1×PBS buffer solution. Then 1ml of 4% formaldehyde (Sigma)/PBS solution was added and incubated 
for 10min at 37ºC. After removal of Formaldehyde/PBS solution the coverslip was rinsed three times with 
1ml of 1×PBS buffer solution. Further 6μl of 1,5μg/ml DAPI (Sigma-Aldrich, 32670)/PBS solution were 
placed at the center of microscopy slide and coverslip was placed upon this droplet with the cells facing 
down. 
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3 RESULTS 
3.1 The Melanocortin System in Fugu: Determination of 
POMC/AGRP/MCR Gene Repertoire and Synteny, As Well As 
Pharmacology and Anatomical Distribution of the MCRs 
 
 
Contributions: 
• Cloning of the Fugu ACTHR coding sequence; 
• Expression of Fugu and human ACTHRs in M3 melanoma cells; 
• Carrying out of cAMP assays on Fugu and human ACTHRs expressed in M3 
melanoma cells; 
• Contribution in a form of discussions to development of hypothetical model which is 
explaining the formation of MCRs encoding genes. 
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3.2 Formation of new genes explains lower intron density in mammalian 
Rhodopsin G protein-coupled receptors. 
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Supplementary Figure 1. The phylogenetic relationship between GPCRs (TMI–TMVII) of 
the human Rhodopsin family, obtained from Fredriksson et al. (2003). The receptors labeled 
with: green was intronless within protein coding sequence, red contained only one intron 
within protein coding sequence, which separated only start or stop codon along with small 
number of surrounding amino acid codons, orange contained intron within conservative 
DRY motif and blue contained intron within motif to similar conservative DRY motif. 
Shaded fields mark Ancestral Receptor Groups (ARG). Coloured circles represent the results 
acquired from BLAST searches and displays the similarities of Ciona intestinalis (red), 
Ciona savignyi (blue), and Caenorhabditis elegans (green) receptors to groups of human 
receptors. 
 
Supplementary Table 1 Total intron densities within whole (CDS) and only seven transmembrane region 
(TM7) coding sequence in human Rhodopsin GPCRs, members of Ancestral Receptor Group and non-
Ancestral Receptor Group members 
    In all receptors In ARG members 
In Non ARG 
members 
Fold 
difference 
ALL CDS 
Total length of CDS 288130 75717 212413  
No. of Introns 363 202 161  
Introns/Kb 1.259847985 2.6678289 0.7579574 3.51 
Only TM7 Regions  
Total length of CDS 193466 45478 147988  
No. of Introns 184 76 108  
Introns/Kb 0.951071506 1.6711377 0.7297889 2.29 
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3.3 Identification of domains responsible for specific membrane 
transport and ligand specificity of the ACTH receptor (MC2R) 
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Supplementary Table 1. Primers and source receptors used in the design of chimeric receptors and 
sequences of standard sequencing primers. 
 
 
Construct Reverse mutant primer (5’-3’) Forward mutant primer (5’-3’) 
5’-end 
Source 
Receptor 
3’end 
Source 
Receptor 
Ch1 AGACAAAAAGACGAGGACAGTCGGAATTAT CTGTCCTCGTCTTTTTGTCTCTCCTGAGGT MC2R MC4R 
Ch2 GCAAAACCACTTGCTCGTAGCACCCTCCAT CTACGAGCAAGTGGTTTTGCCGGAGGAGAT MC4R MC2R 
Ch3 GCCTGGAGATTCTTGTTCTTGGCTAT ATAGCCAAGAACAAGAATCTCCAGG MC4R MC2R 
Ch4 GATATTTTCCAGGGTGATGATAATGGTTTC TCATCACCCTGGAAAATATCCTGATCATA MC4R MC2R 
Ch5 GATGGTGATGTAGCGGTCCACTGCAATTGAAAG CTTTCAATTGCAGTGGACCGCTACATCACCATC MC4R MC2R 
Ch6 GGATGGTCAGTGTGATCGCTCCCTTC GAAGGGAGCGATCACACTGACCATCC MC4R MC2R 
Ch7 CAGGCGCAGTATGGATTCTGAGGACAA CCTCAGAATCCATACTGCGCCTGCTAC MC4R MC2R 
Ch8 CAATGACATTGTCATCGGCTGTGGTTTCAA AGCCGATGACAATGTCATTGACTCGGTGAT Ch3 MC4R 
Ch9 TCATAATGTTGTGGTACCGCAGTGCGTGGA GCGGTACCACAACATTATGACAGTTAAGCG Ch4 MC4R 
Ch10 TGAAGCACACGCAGTAGGGGTTACTTGGGC CCCCTACTGCGTGTGCTTCATGTCTCACTT Ch6 MC4R 
Ch11 AAGGTAATCGCTCCCTTCATGTTGGCTCTGGGGAG CTCCCCAGAGCCAACATGAAGGGAGCGATTACCTT Ch5 MC4R 
Ch12 AGAAGATAGTGATGTAGCGGTCCGCAGC CCGCTACATCACTATCTTCTATGCTCTCCA MC2R MC4R 
Ch13 ACATGGTGATGAAGGTGATCACTGTGGGC GATCACCTTCATCACCATGTTCTTCACCATG MC2R MC4R 
Ch14 GCAAAACCACTTGCTCGTAGCACCCTCCAT CTACGAGCAAGTGGTTTTGCCGGAGGAGAT MC4R Ch12 
Ch15 GCAAAACCACTTGCTCGTAGCACCCTCCAT CTACGAGCAAGTGGTTTTGCCGGAGGAGAT MC4R Ch13 
 
Sequencing 
Primer Primer Sequence    
CEP-F GACAGAGAAGACTCTTGCGTTTCTGAT    
CEP-R CGGCCTCTAGAGTCGACTCATTTGTCA    
GFP-seq-R GCCGTCCAGCTCGACCAGGATGGGCACC    
   
Supplementary Table 2. Glycolysation potential of Asn-Xaa-Ser/Thr N-glycosylation sequons (where 
Xaa is any amino acid except proline) of different melanocortin receptors from five different 
organisms. Analysis was performed using software at http://www.cbs.dtu.dk/services/NetNGlyc/output.php
 
) 
Receptor 
Potential 
1st site 2nd site 3rd site 4th site 
MC1R-Danio_rerio 0.6917 0.6856 0.7544 0.7142 
MC1R-Gallus_gallus 0.5553 0.6091 0.4963  
MC1R-Homo_sapiens 0.3064 0.6703   
MC1R-Mus_musculus 0.7467 0.6548   
MC1R-Takifugu_rubripes 0.7336 0.6467   
ACTHR-Danio_rerio     
ACTHR-Gallus_gallus 0.7973 0.6886   
ACTHR-Homo_sapiens 0.6352 0.525   
ACTHR-Mus_musculus 0.6659 0.4468   
ACTHR-Takifugu_rubripes 0.6843 0.6108   
MC3R-Danio_rerio 0.6036 0.7341 0.7267  
MC3R-Gallus_gallus 0.7129 0.8022 0.7106  
MC3R-Homo_sapiens 0.5997 0.669 0.6779  
MC3R-Mus_musculus 0.6129 0.7494 0.7078  
MC4R-Danio_rerio 0.6502 0.5473   
MC4R-Gallus_gallus 0.7666 0.5564   
MC4R-Homo_sapiens 0.7128 0.7492 0.6507  
MC4R-Mus_musculus 0.6817 0.7343 0.6569  
MC4R-Takifugu_rubripes 0.7518 0.6586   
MC5aR-Danio_rerio 0.1754 0.7163   
MC5bR-Danio_rerio 0.6808 0.7637 0.6173  
MC5R-Gallus_gallus 0.7249 0.679 0.7232  
MC5R-Homo_sapiens 0.5768 0.737 0.6586 0.5978 
MC5R-Mus_musculus 0.7493 0.7493 0.74 0.4516 
MC5R-Takifugu_rubripes 0.5917 0.685 0.6446  
MRAP-Homo_sapiens 0.7290 0.5636   
MRAP-ACTHR-complex 0.7290 0.5636 0.6352 0.525 
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Supplementary Figure 1. Sequence alignment of all chimeras produced in this study. Regions of ACTHR are unshaded; MC4R regions are shaded in black. The 
approximate extents of the transmembrane domains are boxed. 
 
             1                                                     TM1                                  TM2                                        TM3 141 
ACTHR    (1) --------------------MKHIINSYENINNTARNNSDCPRVVLPEEIFFTISIVGVLENLIVLLAVFKNKNLQAPMYFFICSLAISDMLGSLYKIL-------ENILIILRNMGYLKPRGSFETTADD-IIDSLFVLS 
 MC4R    (1) MVNSTHRGMHTSLHLWNRSSYRLHSNASESLGKGYSDGGCYEQLFVSPEVFVTLGVISLLENILVIVAIAKNKNLHSPMYFFICSLAVADMLVSVSNGSETIIITL-------LNSTDTDAQS-FTVNID-NVIDSVICSS 
  Ch1    (1) --------------------MKHIINSYENINNTARNNSDCPRLFVSPEVFVTLGVISLLENILVIVAIAKNKNLHSPMYFFICSLAVADMLVSVSNGSETIIITL-------LNSTDTDAQS-FTVNID-NVIDSVICSS 
  Ch2    (1) MVNSTHRGMHTSLHLWNRSSYRLHSNASESLGKGYSDGGCYEQVVLPEEIFFTISIVGVLENLIVLLAVFKNKNLQAPMYFFICSLAISDMLGSLYKIL-------ENILIILRNMGYLKPRGSFETTADD-IIDSLFVLS 
  Ch3    (1) MVNSTHRGMHTSLHLWNRSSYRLHSNASESLGKGYSDGGCYEQLFVSPEVFVTLGVISLLENILVIVAIAKNKNLQAPMYFFICSLAISDMLGSLYKIL-------ENILIILRNMGYLKPRGSFETTADD-IIDSLFVLS 
  Ch4    (1) MVNSTHRGMHTSLHLWNRSSYRLHSNASESLGKGYSDGGCYEQLFVSPEVFVTLGVISLLENILVIVAIAKNKNLHSPMYFFICSLAVADMLVSVSNGSETIIITLENILIILRNMGYLKPRGSFETTADD-IIDSLFVLS 
  Ch5    (1) MVNSTHRGMHTSLHLWNRSSYRLHSNASESLGKGYSDGGCYEQLFVSPEVFVTLGVISLLENILVIVAIAKNKNLHSPMYFFICSLAVADMLVSVSNGSETIIITL-------LNSTDTDAQS-FTVNID-NVIDSVICSS 
  Ch6    (1) MVNSTHRGMHTSLHLWNRSSYRLHSNASESLGKGYSDGGCYEQLFVSPEVFVTLGVISLLENILVIVAIAKNKNLHSPMYFFICSLAVADMLVSVSNGSETIIITL-------LNSTDTDAQS-FTVNID-NVIDSVICSS 
  Ch7    (1) MVNSTHRGMHTSLHLWNRSSYRLHSNASESLGKGYSDGGCYEQLFVSPEVFVTLGVISLLENILVIVAIAKNKNLHSPMYFFICSLAVADMLVSVSNGSETIIITL-------LNSTDTDAQS-FTVNID-NVIDSVICSS 
  Ch8    (1) MVNSTHRGMHTSLHLWNRSSYRLHSNASESLGKGYSDGGCYEQLFVSPEVFVTLGVISLLENILVIVAIAKNKNLQAPMYFFICSLAISDMLGSLYKIL-------ENILIILRNMGYLKPRGSFETTADDNVIDSVICSS 
  Ch9    (1) MVNSTHRGMHTSLHLWNRSSYRLHSNASESLGKGYSDGGCYEQLFVSPEVFVTLGVISLLENILVIVAIAKNKNLHSPMYFFICSLAVADMLVSVSNGSETIIITLENILIILRNMGYLKPRGSFETTADD-IIDSLFVLS 
 Ch10    (1) MVNSTHRGMHTSLHLWNRSSYRLHSNASESLGKGYSDGGCYEQLFVSPEVFVTLGVISLLENILVIVAIAKNKNLHSPMYFFICSLAVADMLVSVSNGSETIIITL-------LNSTDTDAQS-FTVNID-NVIDSVICSS 
 Ch11    (1) MVNSTHRGMHTSLHLWNRSSYRLHSNASESLGKGYSDGGCYEQLFVSPEVFVTLGVISLLENILVIVAIAKNKNLHSPMYFFICSLAVADMLVSVSNGSETIIITL-------LNSTDTDAQS-FTVNID-NVIDSVICSS 
 Ch12    (1) --------------------MKHIINSYENINNTARNNSDCPRVVLPEEIFFTISIVGVLENLIVLLAVFKNKNLQAPMYFFICSLAISDMLGSLYKIL-------ENILIILRNMGYLKPRGSFETTADD-IIDSLFVLS 
 Ch13    (1) --------------------MKHIINSYENINNTARNNSDCPRVVLPEEIFFTISIVGVLENLIVLLAVFKNKNLQAPMYFFICSLAISDMLGSLYKIL-------ENILIILRNMGYLKPRGSFETTADD-IIDSLFVLS 
 Ch14    (1) MVNSTHRGMHTSLHLWNRSSYRLHSNASESLGKGYSDGGCYEQVVLPEEIFFTISIVGVLENLIVLLAVFKNKNLQAPMYFFICSLAISDMLGSLYKIL-------ENILIILRNMGYLKPRGSFETTADD-IIDSLFVLS 
 Ch15    (1) MVNSTHRGMHTSLHLWNRSSYRLHSNASESLGKGYSDGGCYEQVVLPEEIFFTISIVGVLENLIVLLAVFKNKNLQAPMYFFICSLAISDMLGSLYKIL-------ENILIILRNMGYLKPRGSFETTADD-IIDSLFVLS 
 
             142  TM3                                  TM4                             TM5                                                TM6          282 
ACTHR  (114) LLGSIFSLSVIAADRYITIFHALRYHSIVTMRRTVVVLTVIWTFCTGTGITMVIFSHHVPTVITFTSLFPLMLVFILCLYVHMFLLARSHTRKISTLP-----R--ANMKGAITLTILLGVFIFCWAPFVLHVLLMTFCPS 
 MC4R  (133) LLASICSLLSIAVDRYFTIFYALQYHNIMTVKRVGIIISCIWAACTVSGILFIIYSDSSAVIICLITMFFTMLALMASLYVHMFLMARLHIKRIAVLPGTGAIRQGANMKGAITLTILIGVFVVCWAPFFLHLIFYISCPQ 
  Ch1  (113) LLASICSLLSIAVDRYFTIFYALQYHNIMTVKRVGIIISCIWAACTVSGILFIIYSDSSAVIICLITMFFTMLALMASLYVHMFLMARLHIKRIAVLPGTGAIRQGANMKGAITLTILIGVFVVCWAPFFLHLIFYISCPQ 
  Ch2  (134) LLGSIFSLSVIAADRYITIFHALRYHSIVTMRRTVVVLTVIWTFCTGTGITMVIFSHHVPTVITFTSLFPLMLVFILCLYVHMFLLARSHTRKISTLP-----R--ANMKGAITLTILLGVFIFCWAPFVLHVLLMTFCPS 
  Ch3  (134) LLGSIFSLSVIAADRYITIFHALRYHSIVTMRRTVVVLTVIWTFCTGTGITMVIFSHHVPTVITFTSLFPLMLVFILCLYVHMFLLARSHTRKISTLP-----R--ANMKGAITLTILLGVFIFCWAPFVLHVLLMTFCPS 
  Ch4  (141) LLGSIFSLSVIAADRYITIFHALRYHSIVTMRRTVVVLTVIWTFCTGTGITMVIFSHHVPTVITFTSLFPLMLVFILCLYVHMFLLARSHTRKISTLP-----R--ANMKGAITLTILLGVFIFCWAPFVLHVLLMTFCPS 
  Ch5  (133) LLASICSLLSIAVDRYITIFHALRYHSIVTMRRTVVVLTVIWTFCTGTGITMVIFSHHVPTVITFTSLFPLMLVFILCLYVHMFLLARSHTRKISTLP-----R--ANMKGAITLTILLGVFIFCWAPFVLHVLLMTFCPS 
  Ch6  (133) LLASICSLLSIAVDRYFTIFYALQYHNIMTVKRVGIIISCIWAACTVSGILFIIYSDSSAVIICLITMFFTMLALMASLYVHMFLMARLHIKRIAVLPGTGAIRQGANMKGAITLTILLGVFIFCWAPFVLHVLLMTFCPS 
  Ch7  (133) LLASICSLLSIAVDRYFTIFYALQYHNIMTVKRVGIIISCIWAACTVSGILFIIYSDSSAVIICLITMFFTMLALMASLYVHMFLMARLHIKRIAVLPGTGAIRQGANMKGAITLTILIGVFVVCWAPFFLHLIFYISCPQ 
  Ch8  (135) LLASICSLLSIAVDRYFTIFYALQYHNIMTVKRVGIIISCIWAACTVSGILFIIYSDSSAVIICLITMFFTMLALMASLYVHMFLMARLHIKRIAVLPGTGAIRQGANMKGAITLTILIGVFVVCWAPFFLHLIFYISCPQ 
  Ch9  (141) LLGSIFSLSVIAADRYITIFHALRYHNIMTVKRVGIIISCIWAACTVSGILFIIYSDSSAVIICLITMFFTMLALMASLYVHMFLMARLHIKRIAVLPGTGAIRQGANMKGAITLTILIGVFVVCWAPFFLHLIFYISCPQ 
 Ch10  (133) LLASICSLLSIAVDRYFTIFYALQYHNIMTVKRVGIIISCIWAACTVSGILFIIYSDSSAVIICLITMFFTMLALMASLYVHMFLMARLHIKRIAVLPGTGAIRQGANMKGAITLTILLGVFIFCWAPFVLHVLLMTFCPS 
 Ch11  (133) LLASICSLLSIAVDRYITIFHALRYHSIVTMRRTVVVLTVIWTFCTGTGITMVIFSHHVPTVITFTSLFPLMLVFILCLYVHMFLLARSHTRKISTLP-----R--ANMKGAITLTILIGVFVVCWAPFFLHLIFYISCPQ 
 Ch12  (114) LLGSIFSLSVIAADRYITIFYALQYHNIMTVKRVGIIISCIWAACTVSGILFIIYSDSSAVIICLITMFFTMLALMASLYVHMFLMARLHIKRIAVLPGTGAIRQGANMKGAITLTILIGVFVVCWAPFFLHLIFYISCPQ 
 Ch13  (114) LLGSIFSLSVIAADRYITIFHALRYHSIVTMRRTVVVLTVIWTFCTGTGITMVIFSHHVPTVITFITMFFTMLALMASLYVHMFLMARLHIKRIAVLPGTGAIRQGANMKGAITLTILIGVFVVCWAPFFLHLIFYISCPQ 
 Ch14  (134) LLGSIFSLSVIAADRYITIFYALQYHNIMTVKRVGIIISCIWAACTVSGILFIIYSDSSAVIICLITMFFTMLALMASLYVHMFLMARLHIKRIAVLPGTGAIRQGANMKGAITLTILIGVFVVCWAPFFLHLIFYISCPQ 
 Ch15  (134) LLGSIFSLSVIAADRYITIFHALRYHSIVTMRRTVVVLTVIWTFCTGTGITMVIFSHHVPTVITFITMFFTMLALMASLYVHMFLMARLHIKRIAVLPGTGAIRQGANMKGAITLTILIGVFVVCWAPFFLHLIFYISCPQ 
 
             283               TM7                                   341 
ACTHR  (248) NPYCACYMSLFQVNGMLIMCNAVIDPFIYAFRSPELRDAFKKMIFCSRYW--------- 
 MC4R  (274) NPYCVCFMSHFNLYLILIMCNSIIDPLIYALRSQELRKTFKEIICCYPLGGLCDLSSRY 
  Ch1  (254) NPYCVCFMSHFNLYLILIMCNSIIDPLIYALRSQELRKTFKEIICCYPLGGLCDLSSRY 
  Ch2  (268) NPYCACYMSLFQVNGMLIMCNAVIDPFIYAFRSPELRDAFKKMIFCSRYW--------- 
  Ch3  (268) NPYCACYMSLFQVNGMLIMCNAVIDPFIYAFRSPELRDAFKKMIFCSRYW--------- 
  Ch4  (275) NPYCACYMSLFQVNGMLIMCNAVIDPFIYAFRSPELRDAFKKMIFCSRYW--------- 
  Ch5  (267) NPYCACYMSLFQVNGMLIMCNAVIDPFIYAFRSPELRDAFKKMIFCSRYW--------- 
  Ch6  (274) NPYCACYMSLFQVNGMLIMCNAVIDPFIYAFRSPELRDAFKKMIFCSRYW--------- 
  Ch7  (274) NPYCACYMSLFQVNGMLIMCNAVIDPFIYAFRSPELRDAFKKMIFCSRYW--------- 
  Ch8  (276) NPYCVCFMSHFNLYLILIMCNSIIDPLIYALRSQELRKTFKEIICCYPLGGLCDLSSRY 
  Ch9  (282) NPYCVCFMSHFNLYLILIMCNSIIDPLIYALRSQELRKTFKEIICCYPLGGLCDLSSRY 
 Ch10  (274) NPYCVCFMSHFNLYLILIMCNSIIDPLIYALRSQELRKTFKEIICCYPLGGLCDLSSRY 
 Ch11  (267) NPYCVCFMSHFNLYLILIMCNSIIDPLIYALRSPELRDAFKKMIFCSRYW--------- 
 Ch12  (255) NPYCVCFMSHFNLYLILIMCNSIIDPLIYALRSQELRKTFKEIICCYPLGGLCDLSSRY 
 Ch13  (255) NPYCVCFMSHFNLYLILIMCNSIIDPLIYALRSQELRKTFKEIICCYPLGGLCDLSSRY 
 Ch14  (275) NPYCVCFMSHFNLYLILIMCNSIIDPLIYALRSQELRKTFKEIICCYPLGGLCDLSSRY 
 Ch15  (275) NPYCVCFMSHFNLYLILIMCNSIIDPLIYALRSQELRKTFKEIICCYPLGGLCDLSSRY 
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Supplementary Figure 2. Receptor-EGFP fusion-protein expression levels acquired by direct EGFP 
fluorescence measurements. 
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Supplementary Figure 3. Median values of EGFP/AF-WGA fluorescence intensity ratios from selected 
points on the plasma membrane of each cell. The median values for each cell that met the criteria 
described in Materials and Methods and that were used for analysis of membrane-expression levels are 
enclosed in rectangles. Horizontal lines crossing each rectangle represent the means of the median values 
employed.  
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4 DISCUSSION 
The aim of the research included studies of the MCR family evolution and the first 
task was to identify MCRs in bony fishes Takifugu rubripes and Danio rerio. Orthologs of 
all five mammalian melanocortin receptor subtypes were identified in Danio rerio while 
only four were found in Takifugu rubripes (there were no orthologs for MC3R). After 
identification MCRs coding sequences of Takifugu rubripes were cloned, expressed in 
mammalian cell lines and tested for their pharmacological properties. At that time it was 
already established that mammalian ACTHR is binding solely ACTH and can only be 
expressed in adrenal cell lines or cell lines endogenously expressing other MCRs. It was 
not a surprise therefore that ACTHR of Fugu displayed similar properties, interesting 
however was its expression pattern, ACTHR like other MCRs of Fugu were predominantly 
expressed in CNS and only low level expression was detected in the head of the kidney 
(adrenal cells of the fishes are found intermingling with kidney tissue). These findings are 
varying significantly from recent results acquired during characterisation of MCRs in 
european river lamprey (Lampetra fluviatilis) (Haitina et al. 2007). This jawless fish is 
believed to be very similar to early vertebrates and has two MCRs: MCAR and MCBR 
none of which is expressed in CNS, only in skin (MCAR, MCBR) and liver (MCBR) and 
at lower levels in heart and muscle (MCBR). The best explanation here would be that 
MCRs acquired their new regulatory functions soon after the final formation of this GPCR 
family, which occurred after the split of vertebrate and jawless fish lineages. This 
explanation is also supported by the phylogenetical analysis of MCAR and MCBR. 
Amino-acid sequence of MCAR turned out to be more similar to MC1R while amino-acid 
sequence of MCBR to MC4R, which in mammalians is predominantly expressed in CNS. 
Further, data from lamprey MCRs study are fitting very well in our proposed MCR family 
formation model (results section, first chapter, Fig. 9), although, there are no information 
confirming location of these genes in one locus similar to vertebrate ACTHR/MC5R locus. 
Additionally in regard to MC4Rs being more similar to MCBR than closely related MC5R 
and MC3R, some minor modifications should be implemented. In the improved version 
MC4R has been swapped with the MC3R (Fig. 14) and now is considered to be formed 
during the first duplication of ancestral MCBR gene, while MC3R now is considered to be 
“the youngest” member of the family. Besides sequence similarity this conclusion is also 
supported, although unconvincingly, by the study described in second chapter of results  
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Figure 14. Schematical presentation of hypothetical chain of events that could have 
occurred during the formation of MCR family. MCR genes are depicted as shaded 
boxes. The duplication events are depicted as unshaded boxes located upon the arrow-
line. The first stage was the formation of first melanocortin receptor from Adenosine 
binding receptor (ADOR). The second stage of events included the duplication of 
ancestral MCR. Designation of duplicated receptor genes as MCAR and MCBR is 
adopted from European river lamprey (Lampetra fluviatilis) which has only two MCRs, 
one similar to MC1R and ACTHR and other to MC3R, MC4R and MC5R, thus it is 
plausible that they are highly similar to ancestral MC1/2R and MC3/4/5R. Third stage 
of events included the duplication of MCAR gene to MC1R and MC2R genes and 
duplication MCBR gene to MC3/5R and MC4R genes. MC4R is believed to form 
during this duplication event because of its higher similarity to lamprey MCBR. Fourth 
stage of events included duplication MC3/5R gene to MC3R and MC5R genes. 
Enclosed in shaded frame are ACTHR and MC5R genes which are detected to be 
localized in one locus and have an opposite direction of transcription in all analyzed 
vertebrates. Since such situation is characteristic for local duplication via amplicon 
formation and ACTHR and MC5R are two least similar MCRs it is highly plausible that 
MC2/5R locus must be a direct descendant (or its copy) of original MCR locus which 
was formed during the first stage of events. Enclosed in dashed line frame are genes in 
ancestral MC2/5R locuses. Genomic organization of lamprey MCR genes is yet 
uncovered and might confirm the existence of MCA/BR locus. Existence of ancestral 
MC2/3/5R locus might never be confirmed since there are no “living early 
gnathostomes”. The whole genome duplication is widely believed to take place upon 
transition from craniates to gnathostomes which in our proposed chain of events 
correspond to second stage. 
section where MC3Rs whenever clustered were always located on the separate branch 
along with MC5Rs indicating slightly higher sequence similarity and thus more recent 
common ancestry. (Fig. 15)  
Surprising, however, was the structure of Fugu ACTHR and MC5R genes. Both 
receptor genes contained introns which proved a unique property of Fugu MCR coding 
genes. Even more, one of the MC5R introns and ACTHR intron were located at the same 
position of conservative “DRY” motif coding region. This discovery was even more 
intriguing, because there were observations of vertebrate Rhodopsin GPCRs genes being 
predominantly intronless. Second chapter of the results section describes more detailed 
investigation of this phenomenon where we came to conclusion that genes encoding the 
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Rhodopsin GPCRs are predominantly intronless due to the rapid formation of new genes 
during the early stages of vertebrate evolution, suggesting that introns of Fugu ACTHR 
and MC5R encoding genes must be of a recent origin. During this study we came across a 
number of Rhodopsin GPCRs, located in various clusters of phylogenetic tree developed 
by Fredriksson et al. (2003), with intron at the same position of DRY motif and what’s 
more interesting, there were receptors (also located in various clusters of phylogenetic tree) 
with intron in region that is encoding DRY related motif (motif with similar or identical 
amino-acid sequence, but located elsewhere, not at conservative position). The most 
obvious explanation of this DRY intron phenomenon as suggested by Bryson-Richardson 
et al. (2004) would be that intron at this position is of ancient origin and already existed in 
ancestral GPCR. However our findings of relatively recently inserted Fugu ACTHR and 
MC5R introns and existence of DRY related introns suggested that at least some of these 
introns have inserted recently and it is possible that this insertion occurred through proto-
splice site mechanism.  
During the study described in second chapter of the results section we also acquired 
some indications regarding the origin of MCR family. Here while attempting to divide the 
GPCR of analysed organisms according to GRAFS classification system we noticed that 
not all of clusters were represented in “lower animals”. Detailed investigation revealed 
that, in fact, there are only 13 isolated receptor groups which were present in all analysed 
vertebrates and in at least two of three analysed invertebrate. These groups of receptors 
were subsequently designated as Ancient Receptor Groups (ARG). The search for such 
evolutionary ancient receptors, through the analysis of maximum parsimony 
phylogenetical comparison trees in the MECA group, which is formed by MC, Endothelial 
differentiation (EDG), Cannabinoid receptors (CN) and Adenosine binding (ADO) 
receptors, identified that ADOR is found in all analyzed organisms (Fig. 15). Interestingly, 
the sequence similarity analysis reveals that human MCRs are more similar to human 
ADORs (HMM generated model identity 29%) than to other receptors families of MECA 
cluster (HMM generated model identity 27% with EDGR, 26% with GPR3/6/12 and 24% 
with CNR). It is thus highly probable that ancestral MCR of early chordates most probably 
have evolved from receptor of ADOR family that belongs to ARG (Fig. 14). This 
speculation, if presumed to be true, shows how actually flexible is GPCR system in 
general, because this transition also involved important change of the type of specifically 
bound ligand from nucleotide to peptide. 
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Figure 15. Maximum parsimony phylogenetical comparison trees of GRAFS 
classification system MECA group. In these trees human - Homo sapiens (HS) MECA 
group receptors are phylogenetically co analyzed with the MECA group receptors of a) 
house mouse - Mus musculus (MM), b) zebrafish - Danio rerio (DR), c) fugu -Takifugu 
rubripes (TR), d) transparent sea squirt - Ciona intestinalis (CI), e) pacific transparent 
sea squirt - Ciona savignyi (CS) and f) transparent nematode Caenohabditis elegans 
(CE). This analysis was used to identify receptor families in human that have orthologs 
in other analyzed vertebrate and invertebrate organisms. As clearly visible orthologs of 
ADOR receptor family can be identified in all analyzed organisms, indicating this 
receptor family being ancestral to all other MECA families. In these trees it is also 
visible that MC3R, whenever clustered, is always located on one branch with MC5R 
indicating higher sequence similarity 
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 TR.MC4R
 HS.MC5R
 TR.MC5R
 TR.lcl|scaffold 5982.2402.3713
 HS.ADORA3
 HS.ADORA1
 TR.lcl|scaffold 95.274256.2765
 TR.lcl|scaffold 2922.4199.1388
 HS.ADORA2B
 HS.ADORA2A
 TR.lcl|scaffold 2770.888.4754
 Outgroup.HS.GAR6
74
100
100
100
97
94
90
89
64
100
72
98
98
96
96
77
95
58
95
95
50
61
54
89
77
60
59
73
70
c)  HS.ADORA1
 HS.ADORA3
 HS.ADORA2A
 HS.ADORA2B
 CI.lcl|ci0100138509
 CI.lcl|ci0100147526
 CI.lcl|ci0100154135
 CI.lcl|ci0100148112
 CI.lcl|ci0100145160
 CI.lcl|ci0100137752
 CI.lcl|ci0100131120
 CI.lcl|ci0100148350
 HS.GPR3
 HS.GPR6
 HS.GPR12
 HS.MC2R
 HS.MC1R
 HS.MC4R
 HS.MC3R
 HS.MC5R
 HS.CNR1
 HS.CNR2
 CI.CNR
 HS.EDG2
 HS.EDG7
 HS.EDG4
 HS.EDG6
 HS.EDG1
 HS.EDG3
 HS.EDG8
 HS.EDG5
 CI.lcl|ci0100136887
 CI.lcl|ci0100145235
 CI.lcl|ci0100143300
 CI.lcl|ci0100138955
 CI.lcl|ci0100131828
 CI.lcl|ci0100130574
 CI.lcl|ci0100132478
 CI.lcl|ci0100141764
 Outgroup.HS.GAR6
70
99
99
99
56
72
99
98
84
98
95
93
93
58
66
75
87
53
83
83
50
d)
 
 HS.ADORA1
 HS.ADORA3
 HS.ADORA2A
 HS.ADORA2B
 CS.scaffold 64 peptide 19
 CS.scaffold 367 peptide 358
 HS.CNR1
 HS.CNR2
 HS.EDG2
 HS.EDG7
 HS.EDG4
 HS.EDG6
 HS.EDG1
 HS.EDG3
 HS.EDG5
 HS.EDG8
 HS.GPR3
 HS.GPR12
 HS.GPR6
 HS.MC1R
 HS.MC2R
 HS.MC4R
 HS.MC3R
 HS.MC5R
 Outgroup.HS.GAR6
50
100
100
90
99
63
83
74
99
99
95
76
69
89
84
82
77
83
e)  HS.EDG1
 HS.EDG3
 HS.EDG5
 HS.EDG8
 HS.EDG6
 HS.EDG4
 HS.EDG2
 HS.EDG7
 HS.CNR1
 HS.CNR2
 CE.ADOR
 HS.ADORA1
 HS.ADORA3
 HS.ADORA2A
 HS.ADORA2B
 HS.MC2R
 HS.MC1R
 HS.MC4R
 HS.MC3R
 HS.MC5R
 HS.GPR12
 HS.GPR3
 HS.GPR6
 Outgroup.HS.GAR6
80
100
100
90
99
100
99
79
91
73
99
83
98
98
96
95
77
72
63
f)
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As mentioned previously experiments with fugu ACTHR revealed that it exhibits 
the same properties regarding the expression and ligand binging selectivity, which 
indicated the occurrence of this specialisation on an early stage of vertebrate evolution. 
When thinking of this in a broader picture it seems obvious to presume the presence of 
MRAP, which actually ensures correct transportation and ligand recognition of mammalian 
ACTHR, in bony fishes. Recent finding of gene encoding MRAP2 in zebrafish (Chan et al. 
2009) confirms that this protein was an essential part of melanocortin system already prior 
the split of mammalian and teleost lineages. However this finding is accentuating the 
existence of two important questions: When MRAP was introduced in melanocortin 
system and how this high expression and ligand recognition specificity of the ACTHR is 
achieved? In regard to the first question some speculations can be acquired while 
summarising the information from first chapter of results section, previously mentioned 
lamprey study and one of recently published studies, authors of which declare MRAP and 
MRAP2 being bidirectional regulators of melanocortin receptor trafficking, which couple 
not only to ACTHR, but also to other members of MCR family, thus down-regulating their 
membrane expression (Chan et al. 2009). This later finding if combined with the fact of 
lamprey receptors not being ACTH specific, thus not requiring MRAP, suggests that 
MRAP, most probably, joined MC system only after the formation of first four MC 
receptors and after integration of MC system in regulation mechanisms of CNS. As for its 
initial functions those, most probably, were the regulation of MCR membrane transport. 
Further, from previously described scenario it seems to be obvious that specialisation of 
ACTHR, must have occurred only after the introduction of MRAP in to the MC system 
and my speculation would be that ACTHR expression specificity was the first one to occur 
since it is more close to the proposed initial function of MRAP. (Fig. 16) 
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Figure 16. Schematical presentation of hypothetical chain of events that could have 
occurred during the introduction of MRAP to MC system. Proteins of MC system are 
depicted as shaded boxes, their specific functions as unshaded boxes inside box 
representing specific protein and dashed arrow-lines are pointing to targets of specific 
function. Time line flows for each protein are depicted as solid arrow-lines and specific 
events occurring on them are depicted as unshaded boxes located upon the arrow-line. 
Since none of european river lamprey MCRs are expressed in CNS and none display 
specificity to ACTH it is highly plausible that MRAP was introduced to MC system 
after the split of mammalian and lamprey lineages and possibly after the formation of 
first four. It has been shown that, besides coupling to ACTHR, MRAP also couples to 
other MCRs acting as bidirectional regulator, thus initial function of MRAP must have 
been regulation of MCRs membrane trafficking. Specialization of MC2R (transition to 
ACTHR) must have occurred after the introduction of MRAP and expression specificity 
must have been the first one to occur. 
The answer to the second question, however, cannot be acquired through merely 
theoretical means and since there were no publications of studies addressing it we decided 
to investigate this issue ourselves. Our approach, as described in third chapter of results 
section, was to create a number of chimerical ACTH/MC4 receptors and thus identify 
receptor domains responsible for ligand recognition and expression specificity. The first 
serious problem was the lack of rapid and effective quantification system for membrane 
proteins, because most of already developed methods involved either direct approach of 
protein extraction followed quantification (Scheurer et al. 2005) or, when using fluorescent 
labels, quantification of total cell emission (Vitko et al. 2007) and both of these approaches 
are time consuming. To solve this problem we developed new – quantification of cell-
membrane co-localisation method. Our approach involved acquisition of confocal 
microscopy images of receptor-EGFP fusion-protein expressing cells and measurement of 
EGFP emission at one point of cell membrane. Since such single measurement is not 
sufficient to estimate the average emission of whole membrane and is even less sufficient 
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to estimate the average emission of protein expressing cell population, we measured 
emission intensity at 20 points of cell membrane for six cells from at least two transfection 
experiments (analyzing three or less cells per one experiment), thus in total acquiring 120 
measurements for each expressed receptor. Further results from various receptors were 
compared, searching for significant differences in emission levels. The method itself 
turned out to be rapid, effective and reliable for analysis of a large number of microscopy 
experiments in relatively short period of time, however since it involves the estimation of 
emission differences the acquired quantification is relative and thus it requires the usage of 
references. In our case, the unchanged MC4R and ACTHR EGFP fusion-proteins were 
serving as such maximum and minimum references respectively. The analysis of 
chimerical ACTH/MC4 receptors revealed that, according to relative amount of receptors 
in membrane of the cell, they all can be subdivided in three groups. First group united 
receptors with fluorescence emission level at cell membrane similar to MC4R, second 
group included receptors that resembled ACTHR like fluorescence emission levels and 
third group of receptors with fluorescence emission levels lower than MC4R, but higher 
than ACTHR. Strict division of chimeric receptors in three groups was extraordinary and 
suggested the presence of more than one membrane trafficking regulation element within 
the structure of ACTHR, because intermediate states between maximum and minimum are 
usually achieved through existence of several regulation mechanisms. Detailed analysis 
revealed that indeed there are at least two elements; one located within N-terminal tail of 
the receptor and other within region formed by TM3 and TM4. Since extracellular part of 
the membrane proteins, which in the case of ACTHR includes N-terminus, is almost 
always being glycosylated and usually at multiple sites, the presence of strong 
glycosylation signals is commonly associated with membrane export promoting. In-silico 
analysis of N-termini of ACTHR from various species predicted only two glycosylation 
sites and both with low glycosylation potential, thus we speculated that such low 
glycosylation potential must be significantly decreasing the membrane transport of 
ACTHR molecules. 
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Figure 17. a) Graph representing medians with interquartile ranges of EGFP/AF-WGA 
fluorescence intensity ratio at cell plasma membrane for tested receptors. Bars with 
angled lines correspond to the receptors co-expressed with MRAP-β. b) Schematic 
presentation of the chimeric receptors. Regions from the MC4R are shaded grey, 
regions from the ACTHR are shaded black. 
Because of a sequence based signalling nature the identification of N-termini as 
region containing regulation elements was rather simple, from logical point of view 
however, it was a lot harder to identify the location of second membrane transport 
regulation element. We encountered the difficulties to identify this region because it was a 
tertiary structure based signal which is formed only when both TM3 and TM4 of ACTHR 
are present. Our speculation regarding the nature of this element is that TM3 and TM4 are 
forming intracellular retention signal that is masked or disrupted after receptor coupling to 
MRAP. Our recent-unpublished results are also supporting these findings and as it is 
clearly seen in Fig 17, there was no fluorescence emission detected in the plasmatic 
membrane of BHK cells expressing Ch18-EGFP fusion-protein, which has both TM3 and 
TM4 of ACTHR, while, on the contrary, the emission was detected in the membrane of 
cells expressing Ch16-EGFP fusion-protein which has only TM3 of ACTHR. In order to 
verify that the lack of membrane trafficking of Ch18 was not caused by unspecific 
chimeric receptor misfolding we also co-expressed both receptors with MRAP-β and as 
one can see this promoted the membrane trafficking of Ch18-EGFP, leaving unchanged the 
Ch16-EGFP emission level. The existence of such dual protection system might be 
necessary to avoid “receptor leakage” to the cell membrane, since alone none of the signals 
could ensure complete receptor retention. 
Besides the membrane trafficking analysed in third chapter of results section we 
also tested the functional properties of created chimerical receptors. Acquired results 
indicated that region formed by TM4 and TM5 of ACTHR is responsible for receptor 
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ligand recognition selectivity. Combining this knowledge with the discoveries of MRAP 
anti-parallel dimerisation and its involvement in ligand recognition we developed a model 
of possible interactions within ACTHR/MRAP complex and proposed the possible 
scenario of events which is ensuring the selectivity of ligand recognition. Since it was 
discovered that MRAP forms the anti-parallel dimers prior coupling to ACTHR and that 
region located in the N-terminal tail of MRAP is participating in ligand recognition, we 
proposed that the MRAP monomer whose N-terminus is located on extracellular side of 
membrane is interacting with TM4-TM5 region of ACTHR, thus forming ACTH 
-K-K-R-R- pharmacophore binding pocket, while monomer whose C-terminus is located 
on extracellular side of membrane is interacting with TM3-TM4 region of ACTHR, thus 
masking or “neutralising in another way” the arrest signal which is formed by this region. 
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CONCLUSIONS 
1. Six genes encoding melanocortin receptors were identified in zebrafish - Danio rerio. 
Sequence similarity analysis revealed that there is one ortholog for mammalian MC1R, 
ACTHR, MC3R and MC4R and two orthologs for mammalian MC5R.  
2. Four genes encoding melanocortin receptors were identified in fugu - Takifugu 
rubripes. Sequence similarity analysis revealed that those are orthologs for mammalian 
MC1R, ACTHR, MC4R and MC5R. There were no orthologs of mammalian MC3R. 
3. Expression of Takifugu rubripes ACTHR is limited to adrenal cells lines or cell lines 
expressing endogenous MCRs and, like mammalian orthologue, it binds solely to 
ACTH. 
4. There are 14 ancestral receptor groups (ARGs) spared throughout the Rhodopsin 
GPCR family. These groups are usually small – formed by less than five receptors and 
most of the receptors in these groups contain at least one intron within protein coding 
sequence. 
5. Adenosine binding receptor ARG, which is located in the same MECA cluster as 
MCRs shares higher sequence similarity with MCRs than other MECA families, thus it 
is highly plausible that MCRs family originated from receptor of Adenosine binding 
receptor family 
6. Genes encoding the Rhodopsin GPCRs are predominantly intronless due to the rapid 
formation of new genes during the early stages of vertebrate evolution and since there 
are no introns in MCRs of any other species the introns of Fugu ACTHR and MC5R 
encoding genes must be of a recent origin. 
7. Substitution of MC4R N-terminal part with homologue part from ACTHR significantly 
decreased the membrane trafficking of MC4R and signal localized in third and fourth 
transmembrane region is the main determinant of intracellular trapping of ACTHR. 
112 
MAIN THESIS FOR DEFENCE  
1. Melanocortin receptors have acquired their respective functions in an early stage of 
craniate evolution, since there are no MC receptors in “lower” Chordates, but all five 
types of MC receptors are already found in bony fishes 
2. The Majority of vertebrate GPCRs are intronless due to rapid formation of new genes 
during the course of vertebrate evolution. 
3. N-terminus and TM3-TM5 are regions of ACTHR that are determining receptor 
intracellular retention and ligand recognition specificity. 
4. Developed quantification of cell-membrane co-localization is effective membrane 
export level comparison method. 
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